{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T21:25:47.828374+00:00","company":{"ticker":"SER","cik":1708599,"company_name":"Serina Therapeutics, Inc."},"pagination":{"limit":100,"returned":100,"next_cursor":"2022-12-12T23:59:59+00:00|191877"},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Juvenescence Limited","detail":"notes_offering","count":8,"first_seen":"2023-02-10T23:59:59+00:00","last_seen":"2024-02-14T23:59:59+00:00","evidence_fact_ids":[74990,90673,123460,129494,129495,141917,180198,180199]},{"display_name":"AgeX Therapeutics, Inc.","detail":"merger","count":2,"first_seen":"2023-03-15T23:59:59+00:00","last_seen":"2023-08-30T23:59:59+00:00","evidence_fact_ids":[115977,171699]},{"display_name":"AgeX, Merger Sub","detail":"merger","count":1,"first_seen":"2024-04-01T23:59:59+00:00","last_seen":"2024-04-01T23:59:59+00:00","evidence_fact_ids":[63904]},{"display_name":"Greg Bailey, as lead investor, and certain other investors","detail":"equity_purchase","count":1,"first_seen":"2026-03-23T23:59:59+00:00","last_seen":"2026-03-23T23:59:59+00:00","evidence_fact_ids":[27669]},{"display_name":"holders of its outstanding Senior Unsecured Convertible Promissory Note","detail":"notes_offering","count":1,"first_seen":"2026-03-23T23:59:59+00:00","last_seen":"2026-03-23T23:59:59+00:00","evidence_fact_ids":[27670]}],"lender":[{"display_name":"Juvenescence Limited","detail":"convertible_notes","count":20,"first_seen":"2022-12-16T23:59:59+00:00","last_seen":"2024-04-01T23:59:59+00:00","evidence_fact_ids":[63911,69103,74992,76994,80658,83110,89379,92357,98745,108088,113173,116644,123461,141918,148683,166712,171703,178479,183678,190664]},{"display_name":"Gregory H. Bailey, M.D.","detail":"convertible_notes","count":1,"first_seen":"2025-09-15T23:59:59+00:00","last_seen":"2025-09-15T23:59:59+00:00","evidence_fact_ids":[41391]}],"ma_counterparty":[{"display_name":"AgeX Therapeutics, Inc.","detail":"acquisition","count":1,"first_seen":"2024-04-01T23:59:59+00:00","last_seen":"2024-04-01T23:59:59+00:00","evidence_fact_ids":[63914]},{"display_name":"JuvVentures Limited","detail":"disposition","count":1,"first_seen":"2024-12-26T23:59:59+00:00","last_seen":"2024-12-26T23:59:59+00:00","evidence_fact_ids":[102451]}]},"facts":[{"fact_type":"earnings_release","fact_key":"bfd8da137751bc077b8b783c27a24388b5ad13cc","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2026-05-14T20:05:05+00:00","payload":{"eps_text":"$(0.58) per basic and diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$6.9 million","period_text":"the first quarter ended March 31, 2026","report_date":"2026-05-14","result_type":"reported_results","revenue_text":null},"claim":"Serina Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income $6.9 million, EPS $(0.58) per basic and diluted share.","evidence_excerpt":"Serina Therapeutics, Inc. (\"Serina\" or the \"Company\") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ PlatformTM drug optimization technology, today reported its financial results for the first quarter ended March 31, 2026, along with key business updates.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001708599-26-000036","anchor_url":"https://secwatch.observer/filing/0001708599-26-000036#claim-bfd8da137751bc077b8b783c27a24388b5ad13cc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000036/0001708599-26-000036-index.htm"},{"fact_type":"governance_change","fact_key":"8fe4ffe832030814133ab7dca3e495ce50125c9e","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2026-04-21T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2026-04-15","item_codes_triggered":["5.03"],"summary_text":"Amended and restated bylaws to include provisions relating to appointment and authority of Co-Chairs of the Board of Directors, and conforming updates"},"claim":"Serina Therapeutics, Inc.: Amended and restated bylaws to include provisions relating to appointment and authority of Co-Chairs of the Board of Directors, and conforming updates (effective 2026-04-15).","evidence_excerpt":"On April 15, 2026, the Board of Directors of the Company approved and adopted amended and restated bylaws of the Company (the \" Bylaws \"), effective immediately. The Bylaws include provisions relating to the appointment of Co-Chairs of the Board of Directors, including provisions clarifying that special meetings of stockholders may be called by the Chair or any Co-Chair, that the Chair or any Co-Chair may preside at meetings of stockholders and meetings of the Board of Directors, and that each Co-Chair has the same authority and powers as the Chair of the Board and may act independently of any other Co-Chair, subject to coordination expectations set forth in the Bylaws.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001708599-26-000027","anchor_url":"https://secwatch.observer/filing/0001708599-26-000027#claim-8fe4ffe832030814133ab7dca3e495ce50125c9e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000027/0001708599-26-000027-index.htm"},{"fact_type":"earnings_release","fact_key":"2665892a185b5f7dbbec37ca6b35d667c2fb4ca3","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2026-03-25T23:59:59+00:00","payload":{"eps_text":"$(1.91) per basic and diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$19.4 million","period_text":"the year ended December 31, 2025","report_date":"2026-03-25","result_type":"reported_results","revenue_text":null},"claim":"Serina Therapeutics, Inc. reported the year ended December 31, 2025 results: net income $19.4 million, EPS $(1.91) per basic and diluted share.","evidence_excerpt":"The net loss attributable to Serina common stockholders for the year ended December 31, 2025 was $19.4 million, or $(1.91) per basic and diluted share","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001708599-26-000018","anchor_url":"https://secwatch.observer/filing/0001708599-26-000018#claim-2665892a185b5f7dbbec37ca6b35d667c2fb4ca3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000018/0001708599-26-000018-index.htm"},{"fact_type":"governance_change","fact_key":"823fcc519fa97b02468cf6fefa226d3f63187190","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2026-03-23T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":null,"item_codes_triggered":["5.03"],"summary_text":"Company agreed to amend bylaws to provide for co-chairmen of the Board, with each co-chairman having same rights and responsibilities, effective upon closing of initial tranche of private placement."},"claim":"Serina Therapeutics, Inc.: Company agreed to amend bylaws to provide for co-chairmen of the Board, with each co-chairman having same rights and responsibilities, effective upon closing of initial tranche of private placement.","evidence_excerpt":"the Company has agreed to take all necessary actions to effect such appointment and to amend its bylaws to provide for co-chairmen of the Board, with each co-chairman having the same rights and responsibilities.","confidence":0.4,"filing_url":"https://secwatch.observer/filing/0001708599-26-000010","anchor_url":"https://secwatch.observer/filing/0001708599-26-000010#claim-823fcc519fa97b02468cf6fefa226d3f63187190","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000010/0001708599-26-000010-index.htm"},{"fact_type":"material_agreement","fact_key":"12e7165f5b114ce77a7ee71fa3f6dcc542b9603c","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2026-03-23T23:59:59+00:00","payload":{"action":"amendment","agreement_name":null,"agreement_type":"notes_offering","counterparty":"holders of its outstanding Senior Unsecured Convertible Promissory Note","effective_date":null,"item_codes_triggered":["1.01"],"value_text":null},"claim":"Serina Therapeutics, Inc. amended a notes offering with holders of its outstanding Senior Unsecured Convertible Promissory Note.","evidence_excerpt":"As a condition to the initial closing, the Company and the holders of its outstanding Senior Unsecured Convertible Promissory Note, dated September 9, 2025, entered into an amendment of such note, effective upon the initial closing, removing any further obligations to borrow or loan funds under the Note.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001708599-26-000010","anchor_url":"https://secwatch.observer/filing/0001708599-26-000010#claim-12e7165f5b114ce77a7ee71fa3f6dcc542b9603c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000010/0001708599-26-000010-index.htm"},{"fact_type":"material_agreement","fact_key":"dca61f6f7f16e558d8a6d0a1defbcc4d87d12930","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2026-03-23T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"Greg Bailey, as lead investor, and certain other investors","effective_date":"2026-03-17","item_codes_triggered":["1.01"],"value_text":"$15.0 million"},"claim":"Serina Therapeutics, Inc. entered into Securities Purchase Agreement with Greg Bailey, as lead investor, and certain other investors valued at $15.0 million (effective 2026-03-17).","evidence_excerpt":"On March 17, 2026, Serina Therapeutics, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with Greg Bailey, as lead investor, and certain other investors (collectively, the “ Investors ”), pursuant to which the Company agreed to issue and sell, in a private placement (the “ Private Placement ”), shares of its common stock, par value $0.0001 per share (the “ Common Stock ”), pre-funded warrants to purchase shares of Common Stock (the “ Pre-Funded Warrants ”) redeemable warrants to purchase shares of Common Stock (the “ Redeemable Warrants ” and, together with the Common Stock and the Pre-Funded Warrants, the “ Securities ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001708599-26-000010","anchor_url":"https://secwatch.observer/filing/0001708599-26-000010#claim-dca61f6f7f16e558d8a6d0a1defbcc4d87d12930","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000010/0001708599-26-000010-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"385fb544c2d65205e22969cd1979fd6ef6f14942","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2026-01-15T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2026-02-08","deficiency_type":"stockholders_equity","delisting_effective_date":null,"exchange":"nyse_american","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"$2,000,000","notice_date":"2026-01-09","notice_type":"deficiency_notice","plan_due_date":"2026-02-08","raw_rule_text":null,"reported_value":"$1,600,000","rule_numbers":["1003(a)(i)","1003(a)(ii)","1003(a)(iii)","1009"],"rules_cited_in_text":true},"claim":"Serina Therapeutics, Inc. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii), 1003(a)(iii), 1009).","evidence_excerpt":"January 9, 2026, Serina Therapeutics, Inc. (the “Company”) received a notification (the “Letter”) from The NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the minimum stockholders’ equity requirements of Sections 1003(a)(i), 1003(a)(ii), and 1003(a)(iii) of the NYSE American Company Guide (the “Company Guide”) requiring stockholders’ equity of (i) $2.0 million or more if the Company has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, (ii) $4.0 million or more if the Company has reported losses","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001708599-26-000003","anchor_url":"https://secwatch.observer/filing/0001708599-26-000003#claim-385fb544c2d65205e22969cd1979fd6ef6f14942","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000003/0001708599-26-000003-index.htm"},{"fact_type":"equity_issuance","fact_key":"d9e755a6edfeedc83657af1573b3ccbc3a71f99a","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2025-09-15T23:59:59+00:00","payload":{"action":"warrant_issuance","consideration_text":"exercise price equal to $5.44 per share","effective_date":null,"item_codes_triggered":["3.02"],"purchaser":"Gregory H. Bailey, M.D.","security_type":"warrant","shares_text":"100% of the number of shares issuable upon conversion of the funds extended by the investors on such funding date"},"claim":"Serina Therapeutics, Inc. issued 100% of the number of shares issuable upon conversion of the funds extended by the investors on such funding date of warrant to Gregory H. Bailey, M.D. for exercise price equal to $5.44 per share.","evidence_excerpt":"equal to 100% of the number of shares issuable upon conversion of the funds extended by the investors on such funding date. Such warrants will have an exercise price equal to $5.44 per share. The warrants expire on the earlier of sixty days following the achievement of Milestone 5 or September 30, 2026, unless stockholder approval has not been obtained as","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001708599-25-000110","anchor_url":"https://secwatch.observer/filing/0001708599-25-000110#claim-d9e755a6edfeedc83657af1573b3ccbc3a71f99a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000110/0001708599-25-000110-index.htm"},{"fact_type":"equity_issuance","fact_key":"69f6be33e55651bd516db3ac5b281d1008a99062","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2025-09-15T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"aggregate principal amount of up to $20 million","effective_date":"2025-09-09","item_codes_triggered":["3.02"],"purchaser":"Gregory H. Bailey, M.D.","security_type":"convertible_note","shares_text":null},"claim":"Serina Therapeutics, Inc. issued convertible note to Gregory H. Bailey, M.D. for aggregate principal amount of up to $20 million.","evidence_excerpt":"note (the “Convertible Note”) with Gregory H. Bailey, M.D., a member of the Company’s Board of Directors, making available to the Company an aggregate principal amount of up to $20 million. Under the Convertible Note, borrowings may be drawn in the discretion of the Company in five tranches tied to certain clinical and operational milestones, provided that if at","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001708599-25-000110","anchor_url":"https://secwatch.observer/filing/0001708599-25-000110#claim-69f6be33e55651bd516db3ac5b281d1008a99062","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000110/0001708599-25-000110-index.htm"},{"fact_type":"debt_financing","fact_key":"76754fdbb330ee064eae7dd13ab389ff1085302f","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2025-09-15T23:59:59+00:00","payload":{"counterparty":"Gregory H. Bailey, M.D.","effective_date":"2025-09-09","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"annual rate of 10%","item_codes_triggered":["2.03"],"maturity_text":"five years after the initial funding date","principal_text":"up to $20 million"},"claim":"Serina Therapeutics, Inc. incurred convertible notes of up to $20 million with Gregory H. Bailey, M.D. at annual rate of 10% maturing five years after the initial funding date.","evidence_excerpt":"On September 9, 2025, Serina Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an unsecured convertible note (the “Convertible Note”) with Gregory H. Bailey, M.D., a member of the Company’s Board of Directors, making available to the Company an aggregate principal amount of up to $20 million.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001708599-25-000110","anchor_url":"https://secwatch.observer/filing/0001708599-25-000110#claim-76754fdbb330ee064eae7dd13ab389ff1085302f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000110/0001708599-25-000110-index.htm"},{"fact_type":"governance_change","fact_key":"21d0c0b12dab8a306316da90ae8e0ebbc068778c","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2025-08-22T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2025-08-18","item_codes_triggered":["5.03"],"summary_text":"Amended bylaws to add safe harbor procedures for interested transactions and expand the forum selection clause."},"claim":"Serina Therapeutics, Inc.: Amended bylaws to add safe harbor procedures for interested transactions and expand the forum selection clause (effective 2025-08-18).","evidence_excerpt":"On August 18, 2025, the Board of Directors of Serina Therapeutics, Inc. (the “Company”) amended the Company’s Amended and Restated Bylaws (the “Bylaws Amendment”) to (i) provide a number of safe harbor procedures for acts or transactions involving the Company in which one or more directors or officers as well as controlling stockholders and members of control groups have interests or relationships that might render them interested or not independent with respect to the act or transaction and (ii) supplement the forum selection clause in Section 9.2 of the Company’s Amended and Restated Certificate of Incorporation to expand the coverage of the forum selection clause to include claims of stockholders, when acting in their capacity as stockholders or in the right of the corporation, if such claims relate to the business of the corporation, the conduct of its affairs, or the rights or powers of the corporation or its stockholders, directors or officers.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001708599-25-000101","anchor_url":"https://secwatch.observer/filing/0001708599-25-000101#claim-21d0c0b12dab8a306316da90ae8e0ebbc068778c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000101/0001708599-25-000101-index.htm"},{"fact_type":"executive_change","fact_key":"b5a49a5b57","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2025-05-22T23:59:59+00:00","payload":{"action":"departed","action_category":"departure","departure_tone":"routine","effective_date":"2025-05-22","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Remy Gross departed as Director at Serina Therapeutics, Inc..","evidence_excerpt":"The Company also announced the departure of Remy Gross from its Board of Directors effective May 22, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001708599-25-000058","anchor_url":"https://secwatch.observer/filing/0001708599-25-000058#claim-b5a49a5b57","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000058/0001708599-25-000058-index.htm"},{"fact_type":"executive_change","fact_key":"daf6926ee3","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2025-05-22T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-05-22","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Stephen Brannan was appointed as Director at Serina Therapeutics, Inc..","evidence_excerpt":"On May 22, 2025 , the Board of Directors of Serina Therapeutics, Inc. (the “Company”) appointed Dr. Stephen Brannan to the Company’s Board of Directors, effective May 22, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001708599-25-000058","anchor_url":"https://secwatch.observer/filing/0001708599-25-000058#claim-daf6926ee3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000058/0001708599-25-000058-index.htm"},{"fact_type":"governance_change","fact_key":"a6d7dd52232de2b7c1dcd609e2821b556bb31c2d","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2025-04-14T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-04-10","item_codes_triggered":["5.03"],"summary_text":"Filed Certificate of Designations for Series A Convertible Preferred Stock, establishing rights, preferences, and limitations."},"claim":"Serina Therapeutics, Inc.: Filed Certificate of Designations for Series A Convertible Preferred Stock, establishing rights, preferences, and limitations (effective 2025-04-10).","evidence_excerpt":"On April 10, 2025, the Company filed a Certificate of Designations of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the \"Certificate of Designations\") with the Secretary of State of the State of Delaware, which became effective upon filing.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001708599-25-000042","anchor_url":"https://secwatch.observer/filing/0001708599-25-000042#claim-a6d7dd52232de2b7c1dcd609e2821b556bb31c2d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000042/0001708599-25-000042-index.htm"},{"fact_type":"executive_change","fact_key":"6a5a3b2af4","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2025-02-12T23:59:59+00:00","payload":{"action":"departed","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-11","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Dr. Milton Harris departed as Director at Serina Therapeutics, Inc..","evidence_excerpt":"The Company also announced the departure of Dr. Milton Harris from its Board of Directors effective February 11, 2025 .","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001708599-25-000016","anchor_url":"https://secwatch.observer/filing/0001708599-25-000016#claim-6a5a3b2af4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000016/0001708599-25-000016-index.htm"},{"fact_type":"executive_change","fact_key":"05565eac11","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2025-02-12T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-02-12","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Dr. Jay Venkatesan was appointed as Director at Serina Therapeutics, Inc..","evidence_excerpt":"On February 11, 2025 , the Board of Directors of Serina Therapeutics, Inc. (the “Company”) appointed Dr. Jay Venkatesan to the Company’s Board of Directors, effective February 12, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001708599-25-000016","anchor_url":"https://secwatch.observer/filing/0001708599-25-000016#claim-05565eac11","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000016/0001708599-25-000016-index.htm"},{"fact_type":"executive_change","fact_key":"2b52dc4d3f","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2025-01-15T23:59:59+00:00","payload":{"action":"departed","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Steven Mintz departed as Director at Serina Therapeutics, Inc..","evidence_excerpt":"departure of Steven Mintz from its Board of Directors","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001708599-25-000005","anchor_url":"https://secwatch.observer/filing/0001708599-25-000005#claim-2b52dc4d3f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000005/0001708599-25-000005-index.htm"},{"fact_type":"executive_change","fact_key":"fb6b1b3747","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2025-01-15T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-01-14","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Karen J. Wilson was appointed as Director at Serina Therapeutics, Inc..","evidence_excerpt":"appointment of Karen J. Wilson to the Company’s Board of Directors, effective January 14, 2025","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001708599-25-000005","anchor_url":"https://secwatch.observer/filing/0001708599-25-000005#claim-fb6b1b3747","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000005/0001708599-25-000005-index.htm"},{"fact_type":"ma_transaction","fact_key":"c0af7118cd9b9bf603e1f37d2fcbf259efdc44bb","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-12-26T23:59:59+00:00","payload":{"action":"disposition","closing_date":"2024-12-23","consideration_text":"assumed approximately $11.2 million of secured debt","counterparty":"JuvVentures (UK) Limited","effective_date":"2024-12-23","item_codes_triggered":["2.01"]},"claim":"Serina Therapeutics, Inc. completed a disposition involving JuvVentures (UK) Limited for assumed approximately $11.2 million of secured debt (closed 2024-12-23).","evidence_excerpt":"with the intent to revert aged or diseased cells to a healthy and functional state. As consideration for the purchase of UniverXome, Juvenescence assumed approximately $11.2 million of secured debt owed by UniverXome to Juvenescence in addition to a nominal cash payment. The debt assumed by Juvenescence was secured by substantially all of the assets of","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001708599-24-000033","anchor_url":"https://secwatch.observer/filing/0001708599-24-000033#claim-c0af7118cd9b9bf603e1f37d2fcbf259efdc44bb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859924000033/0001708599-24-000033-index.htm"},{"fact_type":"executive_change","fact_key":"cd95d9576c","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-09-12T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-09-08","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Steven Ledger was appointed as Chief Executive Officer at Serina Therapeutics, Inc..","evidence_excerpt":"On September 8, 2024, the Board of Directors (the “Board”) of Serina Therapeutics, Inc. (the “Company”) appointed Steven Ledger, the current Interim Chief Executive Officer of the Company, to be the Company’s Chief Executive Officer.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-24-036080","anchor_url":"https://secwatch.observer/filing/0001493152-24-036080#claim-cd95d9576c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224036080/0001493152-24-036080-index.htm"},{"fact_type":"executive_change","fact_key":"da6a749964","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-08-16T23:59:59+00:00","payload":{"action":"informed that employment will end","action_category":"departure","departure_tone":"routine","effective_date":"2024-08-15","interim":false,"role":"Interim Chief Financial Officer and Chief Accounting Officer","role_category":"cfo","successor_name":"Gregory S. Curhan","successor_named":true},"claim":"Andrea Park departed as Interim Chief Financial Officer and Chief Accounting Officer at Serina Therapeutics, Inc..","evidence_excerpt":"On August 12, 2024, the Company informed Andrea Park, the Company’s Interim Chief Financial Officer and Chief Accounting Officer, that her employment with the Company will end effective August 15, 2024.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-24-032700","anchor_url":"https://secwatch.observer/filing/0001493152-24-032700#claim-da6a749964","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224032700/0001493152-24-032700-index.htm"},{"fact_type":"executive_change","fact_key":"5989ce3c44","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-08-16T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-08-16","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Gregory S. Curhan was appointed as Chief Financial Officer at Serina Therapeutics, Inc..","evidence_excerpt":"On August 15, 2024, the Board of Directors (the “Board”) of Serina Therapeutics, Inc. (the “Company”) appointed Gregory S. Curhan as the Company’s Chief Financial Officer in a non-employee consultant role, effective August 16, 2024.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-24-032700","anchor_url":"https://secwatch.observer/filing/0001493152-24-032700#claim-5989ce3c44","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224032700/0001493152-24-032700-index.htm"},{"fact_type":"executive_change","fact_key":"7518916398","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-07-18T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-07-15","interim":false,"role":"Senior Vice President, CMC & Formulation","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Srini Tenjarla was appointed as Senior Vice President, CMC & Formulation at Serina Therapeutics, Inc..","evidence_excerpt":"On July 18, 2024, Serina Therapeutics, Inc. (the “ Company ”) announced the hiring of Dr. Srini Tenjarla as Senior Vice President, CMC & Formulation.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-028363","anchor_url":"https://secwatch.observer/filing/0001493152-24-028363#claim-7518916398","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224028363/0001493152-24-028363-index.htm"},{"fact_type":"executive_change","fact_key":"cb2d80e0f8","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-07-12T23:59:59+00:00","payload":{"action":"retire","action_category":"departure","departure_tone":"retirement","effective_date":"2024-07-15","interim":false,"role":"Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Tacey Viegas departed as Chief Operating Officer at Serina Therapeutics, Inc..","evidence_excerpt":"On July 9, 2024, Tacey Viegas, Chief Operating Officer of Serina Therapeutics, Inc. (the “ Company ”), notified the Company that he will retire effective July 15, 2024","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-027113","anchor_url":"https://secwatch.observer/filing/0001493152-24-027113#claim-cb2d80e0f8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224027113/0001493152-24-027113-index.htm"},{"fact_type":"earnings_release","fact_key":"86c75a5d733c5ecde3d32328133ee848b7815e4b","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-05-14T23:59:59+00:00","payload":{"eps_text":"($3.38) per share (basic and diluted)","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$9.4 million, or ($3.38) per share (basic and diluted)","period_text":"the quarter ended March 31, 2024","report_date":"2024-05-14","result_type":"reported_results","revenue_text":"$5,000 and $30,000 for the first quarter of 2024 and in the same period in 2023, respectively"},"claim":"Serina Therapeutics, Inc. reported the quarter ended March 31, 2024 results: revenue $5,000 and $30,000 for the first quarter of 2024 and in the same period in 2023, respectively, net income $9.4 million, or ($3.38) per share (basic and diluted), EPS ($3.38) per share (basic and diluted).","evidence_excerpt":"On May 14, 2024, the Company announced its financial results for the quarter ended March 31, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-019262","anchor_url":"https://secwatch.observer/filing/0001493152-24-019262#claim-86c75a5d733c5ecde3d32328133ee848b7815e4b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224019262/0001493152-24-019262-index.htm"},{"fact_type":"auditor_change","fact_key":"18feb64157cc71ca2b8fea8077b095e4e692db6b","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-05-03T23:59:59+00:00","payload":{"action":"dismissal","auditor_name":"WithumSmith+Brown, PC","disagreement_text":"there were no \"disagreements\" (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and related instructions) between the Company and Withum on any matters of accounting principles or practices, financial statement disclosure or auditing scope and procedures which, if not resolved to the satisfaction of Withum, would have caused Withum to make reference to the subject matter of the disagreement in their reports.","effective_date":"2024-04-29","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":"Frazier & Deeter, LLC"},"claim":"Serina Therapeutics, Inc. dismissed WithumSmith+Brown, PC as its auditor.","evidence_excerpt":"ithumSmith+Brown, PC (“ Withum ”), the Company’s independent registered public accounting firm prior to\nthe Merger, was informed that it would be dismissed and replaced by Frazier & Deeter. The\nreports of Withum on the Company’s financial statements for each of the two fiscal years ended December 31, 2023 and 2022 did not","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-017731","anchor_url":"https://secwatch.observer/filing/0001493152-24-017731#claim-18feb64157cc71ca2b8fea8077b095e4e692db6b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224017731/0001493152-24-017731-index.htm"},{"fact_type":"auditor_change","fact_key":"7fd607aa7f408e9e4ae6769189335e52610aee0a","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-05-03T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"Frazier & Deeter, LLC","disagreement_text":null,"effective_date":"2024-04-29","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"Serina Therapeutics, Inc. engaged Frazier & Deeter, LLC as its auditor.","evidence_excerpt":"pril 29, 2024, the Audit Committee of the Board of Directors of the Company approved, on behalf of the Company, the engagement of Frazier\n& Deeter, LLC (“ Frazier & Deeter ”) as the Company’s independent registered public accounting","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-017731","anchor_url":"https://secwatch.observer/filing/0001493152-24-017731#claim-7fd607aa7f408e9e4ae6769189335e52610aee0a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224017731/0001493152-24-017731-index.htm"},{"fact_type":"executive_change","fact_key":"cf0c39d001","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-04-17T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-04-12","interim":false,"role":"Executive Chairman","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Simba Gill was appointed as Executive Chairman at Serina Therapeutics, Inc..","evidence_excerpt":"On April 17, 2024, Serina Therapeutics, Inc. (the “Company”) announced the appointment of Simba Gill, Ph.D., as the Company’s Chairman of the Board of Directors, effective as of April 12, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-015037","anchor_url":"https://secwatch.observer/filing/0001493152-24-015037#claim-cf0c39d001","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224015037/0001493152-24-015037-index.htm"},{"fact_type":"governance_change","fact_key":"f599a090abb9be77003c4e82979331969c9a97a6","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-04-01T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2024-03-26","item_codes_triggered":["5.03"],"summary_text":"Name change from AgeX Therapeutics, Inc. to Serina Therapeutics, Inc. via Amended Certificate after Merger"},"claim":"Serina Therapeutics, Inc.: Name change from AgeX Therapeutics, Inc. to Serina Therapeutics, Inc. via Amended Certificate after Merger (effective 2024-03-26).","evidence_excerpt":"Immediately after the consummation of the Merger, on March 26, 2024, AgeX filed the Amended Certificate changing its name from \"AgeX Therapeutics, Inc.\" to \"Serina Therapeutics, Inc.\"","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-012530","anchor_url":"https://secwatch.observer/filing/0001493152-24-012530#claim-f599a090abb9be77003c4e82979331969c9a97a6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224012530/0001493152-24-012530-index.htm"},{"fact_type":"ma_transaction","fact_key":"46975ab0e054f83307ea384bbca03f52d3a490e8","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-04-01T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2024-03-26","consideration_text":"issuance by AgeX of an aggregate of 5,913,277 shares of AgeX common stock","counterparty":"AgeX Therapeutics, Inc.","effective_date":"2024-03-26","item_codes_triggered":["2.01","5.01"]},"claim":"Serina Therapeutics, Inc. completed an acquisition involving AgeX Therapeutics, Inc. for issuance by AgeX of an aggregate of 5,913,277 shares of AgeX common stock (closed 2024-03-26).","evidence_excerpt":"arch 26, 2024, the Delaware corporation formerly known as “AgeX Therapeutics, Inc.” completed its previously announced merger\ntransaction in accordance with the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated as of August 29,","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-012530","anchor_url":"https://secwatch.observer/filing/0001493152-24-012530#claim-46975ab0e054f83307ea384bbca03f52d3a490e8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224012530/0001493152-24-012530-index.htm"},{"fact_type":"debt_financing","fact_key":"1fbd5ddefd0bc5d29f4cb23060ec56b946d748b7","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-04-01T23:59:59+00:00","payload":{"counterparty":"Juvenescence Limited","effective_date":"2024-03-26","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":null,"principal_text":"an additional $2.4 million"},"claim":"Serina Therapeutics, Inc. incurred convertible notes of an additional $2.4 million with Juvenescence Limited.","evidence_excerpt":"pursuant to which AgeX drew an additional $2.4 million of its credit available under the 2022 Convertible Note","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-012530","anchor_url":"https://secwatch.observer/filing/0001493152-24-012530#claim-1fbd5ddefd0bc5d29f4cb23060ec56b946d748b7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224012530/0001493152-24-012530-index.htm"},{"fact_type":"material_agreement","fact_key":"fe22847f74049ca0caed0d4693348a77045da4ac","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-04-01T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Merger Agreement","agreement_type":"merger","counterparty":"AgeX, Merger Sub","effective_date":"2024-03-26","item_codes_triggered":["1.01"],"value_text":null},"claim":"Serina Therapeutics, Inc. entered into Merger Agreement with AgeX, Merger Sub (effective 2024-03-26).","evidence_excerpt":"reviously disclosed, on August 29, 2023, AgeX, Merger Sub and Serina entered into the Merger Agreement. Upon the terms and subject to","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0001493152-24-012530","anchor_url":"https://secwatch.observer/filing/0001493152-24-012530#claim-fe22847f74049ca0caed0d4693348a77045da4ac","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224012530/0001493152-24-012530-index.htm"},{"fact_type":"executive_change","fact_key":"2ba84da88b","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-04-01T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-03-26","interim":false,"role":"Class III Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Richard Marshall was appointed as Class III Director at Serina Therapeutics, Inc..","evidence_excerpt":"ey and Dr. Richard Marshall, appointed as Class III directors","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-012530","anchor_url":"https://secwatch.observer/filing/0001493152-24-012530#claim-2ba84da88b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224012530/0001493152-24-012530-index.htm"},{"fact_type":"executive_change","fact_key":"1bb7aef69c","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-04-01T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-03-26","interim":false,"role":"Class III Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Gregory M. Bailey was appointed as Class III Director at Serina Therapeutics, Inc..","evidence_excerpt":"The Company’s board of directors appointed the following members to the Compensation Committee: J. Milton Harris, Ph.D. (Chair), Gregory M. Bailey, M.D., and Steven Mintz.","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0001493152-24-012530","anchor_url":"https://secwatch.observer/filing/0001493152-24-012530#claim-1bb7aef69c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224012530/0001493152-24-012530-index.htm"},{"fact_type":"executive_change","fact_key":"20386dbae0","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-04-01T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-03-26","interim":false,"role":"Chairman of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"J. Milton Harris was appointed as Chairman of the Board at Serina Therapeutics, Inc..","evidence_excerpt":"Dr. Harris was appointed Chairman of the Company’s board of directors.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-012530","anchor_url":"https://secwatch.observer/filing/0001493152-24-012530#claim-20386dbae0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224012530/0001493152-24-012530-index.htm"},{"fact_type":"executive_change","fact_key":"4d31baa848","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-04-01T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-03-26","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Jean-Christophe Renondin resigned as Director at Serina Therapeutics, Inc..","evidence_excerpt":"Dr. Jean-Christophe Renondin resigned from AgeX’s board of directors","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-012530","anchor_url":"https://secwatch.observer/filing/0001493152-24-012530#claim-4d31baa848","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224012530/0001493152-24-012530-index.htm"},{"fact_type":"executive_change","fact_key":"4a20beb93e","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-04-01T23:59:59+00:00","payload":{"action":"resigned and terminated","action_category":"departure","departure_tone":"routine","effective_date":"2024-03-26","interim":false,"role":"Interim Chief Executive Officer and Director","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Joanne M. Hackett departed as Interim Chief Executive Officer and Director at Serina Therapeutics, Inc..","evidence_excerpt":"both Dr. Joanne M. Hackett and Dr. Jean-Christophe Renondin resigned from AgeX’s board of directors and all respective committee membership of AgeX’s board of directors, effective as of the effective time of the Merger and (ii) Dr. Hackett was terminated as interim CEO of the Company effective as of the effective time of the Merger.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-012530","anchor_url":"https://secwatch.observer/filing/0001493152-24-012530#claim-4a20beb93e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224012530/0001493152-24-012530-index.htm"},{"fact_type":"earnings_release","fact_key":"b8d1913f78e0bf488cfb945ac978bb8cb862af0c","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-03-22T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"fourth quarter and fiscal year ended December 31, 2023","report_date":"2024-03-22","result_type":"reported_results","revenue_text":null},"claim":"Serina Therapeutics, Inc. reported financial results for fourth quarter and fiscal year ended December 31, 2023.","evidence_excerpt":"On March 22, 2024, AgeX issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-011024","anchor_url":"https://secwatch.observer/filing/0001493152-24-011024#claim-b8d1913f78e0bf488cfb945ac978bb8cb862af0c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224011024/0001493152-24-011024-index.htm"},{"fact_type":"governance_change","fact_key":"2d1fa5bffa2642d20dc8dedb9ddf69fa31498a8f","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-03-14T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2024-03-14","item_codes_triggered":["5.03"],"summary_text":"Amended the Certificate of Incorporation to effect a 1-for-35.17 reverse stock split of common stock."},"claim":"Serina Therapeutics, Inc.: Amended the Certificate of Incorporation to effect a 1-for-35.17 reverse stock split of common stock (effective 2024-03-14).","evidence_excerpt":"To effect the Reverse Stock Split, AgeX filed a Certificate of Amendment to the AgeX Charter (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware, with an effective time of 10:00 a.m. Eastern Time on March 14, 2024 (the “Effective Time”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-009959","anchor_url":"https://secwatch.observer/filing/0001493152-24-009959#claim-2d1fa5bffa2642d20dc8dedb9ddf69fa31498a8f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224009959/0001493152-24-009959-index.htm"},{"fact_type":"shareholder_vote","fact_key":"fc40e96f172b35d6f98d62bcda0ac996da910823","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-03-14T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-03-14","outcome":"passed","proposal_text":"Proposal No. 6 – To approve the Serina Therapeutics, Inc. 2024 Equity Incentive Plan, in the form attached as Annex C to the Proxy Statement/Prospectus/Information Statement.","proposal_type":"equity_plan","results":[{"broker_non_votes":"437,873","subject":null,"votes_abstain":"71,784","votes_against":"8,360,752","votes_for":"71,363,789","votes_withheld":"0"}]},"claim":"Serina Therapeutics, Inc. shareholders approved Proposal No. 6 – To approve the Serina Therapeutics, Inc. 2024 Equity Incentive Plan, in the form attached as Annex C to the Proxy Statement/Prospectus/Information Statement. at the 2024-03-14 meeting.","evidence_excerpt":"Proposal No. 6 – To approve the Serina Therapeutics, Inc. 2024 Equity Incentive Plan, in the form attached as Annex C to the Proxy Statement/Prospectus/Information Statement. Votes  Non-Votes 71,363,789 8,360,752 71,784 437,873","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-24-009959","anchor_url":"https://secwatch.observer/filing/0001493152-24-009959#claim-fc40e96f172b35d6f98d62bcda0ac996da910823","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224009959/0001493152-24-009959-index.htm"},{"fact_type":"shareholder_vote","fact_key":"8518fce15e0db2770f2e0f6e73258f886c7fd566","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-03-14T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-03-14","outcome":"passed","proposal_text":"Proposal No. 5 – To approve, on a non-binding, advisory basis, eight separately presented governance provisions in the Combined Company Charter , which were separately presented in accordance with SEC guidance and which were voted upon on a non-binding, advisory basis: (H) To provide for the forum s","proposal_type":"say_on_pay","results":[{"broker_non_votes":"4,520,288","subject":null,"votes_abstain":"64,793","votes_against":"6,695,768","votes_for":"68,953,348","votes_withheld":"0"}]},"claim":"Serina Therapeutics, Inc. shareholders approved Proposal No. 5 – To approve, on a non-binding, advisory basis, eight separately presented governance provisions in the Combined Company Charter , which were separately presented in accordance with SEC guidance and which were voted upon on a non-binding, advisory basis: (H) To provide for the forum s at the 2024-03-14 meeting.","evidence_excerpt":"(H) To provide for the forum selection provisions in the Combined Company Charter. Votes  Non-Votes 68,953,348 6,695,768 64,793 4,520,288","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-24-009959","anchor_url":"https://secwatch.observer/filing/0001493152-24-009959#claim-8518fce15e0db2770f2e0f6e73258f886c7fd566","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224009959/0001493152-24-009959-index.htm"},{"fact_type":"shareholder_vote","fact_key":"16fc1a2a1d3fdc581a8b4a6d51e166b237d8f81c","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-03-14T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-03-14","outcome":"passed","proposal_text":"Proposal No. 5 – To approve, on a non-binding, advisory basis, eight separately presented governance provisions in the Combined Company Charter , which were separately presented in accordance with SEC guidance and which were voted upon on a non-binding, advisory basis: (G) To authorize provisions li","proposal_type":"say_on_pay","results":[{"broker_non_votes":"4,520,288","subject":null,"votes_abstain":"82,866","votes_against":"6,789,599","votes_for":"68,841,445","votes_withheld":"0"}]},"claim":"Serina Therapeutics, Inc. shareholders approved Proposal No. 5 – To approve, on a non-binding, advisory basis, eight separately presented governance provisions in the Combined Company Charter , which were separately presented in accordance with SEC guidance and which were voted upon on a non-binding, advisory basis: (G) To authorize provisions li at the 2024-03-14 meeting.","evidence_excerpt":"(G) To authorize provisions limiting personal liability for officers of the combined company for monetary damages for breach of fiduciary duty as an officer to the extent permissible under the DGCL; and Votes  Non-Votes 68,841,445 6,789,599 82,866 4,520,288","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-24-009959","anchor_url":"https://secwatch.observer/filing/0001493152-24-009959#claim-16fc1a2a1d3fdc581a8b4a6d51e166b237d8f81c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224009959/0001493152-24-009959-index.htm"},{"fact_type":"shareholder_vote","fact_key":"141c6a7acb38f1bb42e0cd1cd8c61277c4a6c585","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-03-14T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-03-14","outcome":"passed","proposal_text":"Proposal No. 5 – To approve, on a non-binding, advisory basis, eight separately presented governance provisions in the Combined Company Charter , which were separately presented in accordance with SEC guidance and which were voted upon on a non-binding, advisory basis: (F) To provide that any action","proposal_type":"say_on_pay","results":[{"broker_non_votes":"4,520,288","subject":null,"votes_abstain":"45,507","votes_against":"6,797,084","votes_for":"68,871,319","votes_withheld":"0"}]},"claim":"Serina Therapeutics, Inc. shareholders approved Proposal No. 5 – To approve, on a non-binding, advisory basis, eight separately presented governance provisions in the Combined Company Charter , which were separately presented in accordance with SEC guidance and which were voted upon on a non-binding, advisory basis: (F) To provide that any action at the 2024-03-14 meeting.","evidence_excerpt":"(F) To provide that any action required or permitted to be taken by stockholders of the combined company must be effected at a duly called annual or special meeting of stockholders and may not be effected by a consent or consents (written, electronic, or otherwise) of such stockholders; Votes  Non-Votes 68,871,319 6,797,084 45,507 4,520,288","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-24-009959","anchor_url":"https://secwatch.observer/filing/0001493152-24-009959#claim-141c6a7acb38f1bb42e0cd1cd8c61277c4a6c585","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224009959/0001493152-24-009959-index.htm"},{"fact_type":"shareholder_vote","fact_key":"e934f96faf750adb0d9be17c85f256605261e8ec","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-03-14T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-03-14","outcome":"passed","proposal_text":"Proposal No. 5 – To approve, on a non-binding, advisory basis, eight separately presented governance provisions in the Combined Company Charter , which were separately presented in accordance with SEC guidance and which were voted upon on a non-binding, advisory basis: (E) To create a classified boa","proposal_type":"say_on_pay","results":[{"broker_non_votes":"4,520,288","subject":null,"votes_abstain":"22,922","votes_against":"6,459,281","votes_for":"69,231,707","votes_withheld":"0"}]},"claim":"Serina Therapeutics, Inc. shareholders approved Proposal No. 5 – To approve, on a non-binding, advisory basis, eight separately presented governance provisions in the Combined Company Charter , which were separately presented in accordance with SEC guidance and which were voted upon on a non-binding, advisory basis: (E) To create a classified boa at the 2024-03-14 meeting.","evidence_excerpt":"(E) To create a classified board of directors consisting of three classes, Class I, Class II and Class III, with members of each class elected for three-year terms expiring in sequential years; Votes  Non-Votes 69,231,707 6,459,281 22,922 4,520,288","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-24-009959","anchor_url":"https://secwatch.observer/filing/0001493152-24-009959#claim-e934f96faf750adb0d9be17c85f256605261e8ec","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224009959/0001493152-24-009959-index.htm"},{"fact_type":"shareholder_vote","fact_key":"111af612d87dc04d1ea1ea3c2df8eac3dbfd2cbe","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-03-14T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-03-14","outcome":"passed","proposal_text":"Proposal No. 5 – To approve, on a non-binding, advisory basis, eight separately presented governance provisions in the Combined Company Charter , which were separately presented in accordance with SEC guidance and which were voted upon on a non-binding, advisory basis: (D) To require the affirmative","proposal_type":"say_on_pay","results":[{"broker_non_votes":"4,520,288","subject":null,"votes_abstain":"78,192","votes_against":"7,755,889","votes_for":"67,879,829","votes_withheld":"0"}]},"claim":"Serina Therapeutics, Inc. shareholders approved Proposal No. 5 – To approve, on a non-binding, advisory basis, eight separately presented governance provisions in the Combined Company Charter , which were separately presented in accordance with SEC guidance and which were voted upon on a non-binding, advisory basis: (D) To require the affirmative at the 2024-03-14 meeting.","evidence_excerpt":"(D) To require the affirmative vote of the holders of at least two-thirds of the combined company’s capital stock entitled to vote generally in an election of directors, voting together as a single class, is required to make, alter amend or repeal the bylaws of the combined company or to adopt any provision inconsistent therewith; Votes  Non-Votes 67,879,829 7,755,889 78,192 4,520,288","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-24-009959","anchor_url":"https://secwatch.observer/filing/0001493152-24-009959#claim-111af612d87dc04d1ea1ea3c2df8eac3dbfd2cbe","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224009959/0001493152-24-009959-index.htm"},{"fact_type":"shareholder_vote","fact_key":"522c7d9399af2d6d9e199ce7506d048a89e83bb8","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-03-14T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-03-14","outcome":"passed","proposal_text":"Proposal No. 5 – To approve, on a non-binding, advisory basis, eight separately presented governance provisions in the Combined Company Charter , which were separately presented in accordance with SEC guidance and which were voted upon on a non-binding, advisory basis: (C) To require that any provis","proposal_type":"say_on_pay","results":[{"broker_non_votes":"4,520,288","subject":null,"votes_abstain":"40,793","votes_against":"6,464,926","votes_for":"69,208,191","votes_withheld":"0"}]},"claim":"Serina Therapeutics, Inc. shareholders approved Proposal No. 5 – To approve, on a non-binding, advisory basis, eight separately presented governance provisions in the Combined Company Charter , which were separately presented in accordance with SEC guidance and which were voted upon on a non-binding, advisory basis: (C) To require that any provis at the 2024-03-14 meeting.","evidence_excerpt":"(C) To require that any provision of Articles 5, 6, 7, 8, and 9 of the Combined Company Charter can only be altered, amended or repealed, or any provision inconsistent therewith can only be adopted, upon the affirmative vote of the holders of at least two-thirds of the combined company’s capital stock entitled to vote generally in an election of directors, voting together as a single class; Votes  Non-Votes 69,208,191 6,464,926 40,793 4,520,288","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-24-009959","anchor_url":"https://secwatch.observer/filing/0001493152-24-009959#claim-522c7d9399af2d6d9e199ce7506d048a89e83bb8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224009959/0001493152-24-009959-index.htm"},{"fact_type":"shareholder_vote","fact_key":"31334faa45c3e0cdbff161bc79caf3185f905875","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-03-14T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-03-14","outcome":"passed","proposal_text":"Proposal No. 5 – To approve, on a non-binding, advisory basis, eight separately presented governance provisions in the Combined Company Charter , which were separately presented in accordance with SEC guidance and which were voted upon on a non-binding, advisory basis: (B) To provide that the number","proposal_type":"say_on_pay","results":[{"broker_non_votes":"4,520,288","subject":null,"votes_abstain":"73,803","votes_against":"6,447,684","votes_for":"69,192,423","votes_withheld":"0"}]},"claim":"Serina Therapeutics, Inc. shareholders approved Proposal No. 5 – To approve, on a non-binding, advisory basis, eight separately presented governance provisions in the Combined Company Charter , which were separately presented in accordance with SEC guidance and which were voted upon on a non-binding, advisory basis: (B) To provide that the number at the 2024-03-14 meeting.","evidence_excerpt":"(B) To provide that the number of authorized shares of common stock or preferred stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority in voting power of the stock entitled to vote thereon irrespective of the provisions of Section 242(b)(2) of the Delaware General Corporation Law (“DGCL”); Votes  Non-Votes 69,192,423 6,447,684 73,803 4,520,288","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-24-009959","anchor_url":"https://secwatch.observer/filing/0001493152-24-009959#claim-31334faa45c3e0cdbff161bc79caf3185f905875","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224009959/0001493152-24-009959-index.htm"},{"fact_type":"shareholder_vote","fact_key":"810c2f06b10d5444584627e52e63e25b30fb815b","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-03-14T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-03-14","outcome":"passed","proposal_text":"Proposal No. 5 – To approve, on a non-binding, advisory basis, eight separately presented governance provisions in the Combined Company Charter , which were separately presented in accordance with SEC guidance and which were voted upon on a non-binding, advisory basis: (A) To authorize the issuance","proposal_type":"say_on_pay","results":[{"broker_non_votes":"4,520,288","subject":null,"votes_abstain":"34,239","votes_against":"6,714,611","votes_for":"68,965,060","votes_withheld":"0"}]},"claim":"Serina Therapeutics, Inc. shareholders approved Proposal No. 5 – To approve, on a non-binding, advisory basis, eight separately presented governance provisions in the Combined Company Charter , which were separately presented in accordance with SEC guidance and which were voted upon on a non-binding, advisory basis: (A) To authorize the issuance at the 2024-03-14 meeting.","evidence_excerpt":"(A) To authorize the issuance of 40,000,000 shares of common stock and 5,000,000 shares of preferred stock; Votes  Non-Votes 68,965,060 6,714,611 34,239 4,520,288","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-24-009959","anchor_url":"https://secwatch.observer/filing/0001493152-24-009959#claim-810c2f06b10d5444584627e52e63e25b30fb815b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224009959/0001493152-24-009959-index.htm"},{"fact_type":"shareholder_vote","fact_key":"ff294c7e8621dbb684327606ebeadac782ce58e1","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-03-14T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-03-14","outcome":"passed","proposal_text":"Proposal No. 4 – To approve an amendment and restatement of the AgeX Charter (the “Combined Company Charter”), in the form attached as Annex B to the Proxy Statement/Prospectus/Information Statement.","proposal_type":"charter_amendment","results":[{"broker_non_votes":"4,520,288","subject":null,"votes_abstain":"59,789","votes_against":"7,040,014","votes_for":"68,614,107","votes_withheld":"0"}]},"claim":"Serina Therapeutics, Inc. shareholders approved Proposal No. 4 – To approve an amendment and restatement of the AgeX Charter (the “Combined Company Charter”), in the form attached as Annex B to the Proxy Statement/Prospectus/Information Statement. at the 2024-03-14 meeting.","evidence_excerpt":"Proposal No. 4 – To approve an amendment and restatement of the AgeX Charter (the “Combined Company Charter”), in the form attached as Annex B to the Proxy Statement/Prospectus/Information Statement. Votes  Non-Votes 68,614,107 7,040,014 59,789 4,520,288","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-24-009959","anchor_url":"https://secwatch.observer/filing/0001493152-24-009959#claim-ff294c7e8621dbb684327606ebeadac782ce58e1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224009959/0001493152-24-009959-index.htm"},{"fact_type":"shareholder_vote","fact_key":"534783b8af64f79b32f3984847b4d1f1ce0d961a","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-03-14T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-03-14","outcome":"passed","proposal_text":"Proposal No. 3 – To approve the issuance of the post-merger warrants to holders of AgeX common stock pursuant to the terms of the Merger Agreement, the potential issuance of the incentive warrants and the shares of AgeX common stock upon the exercise of the post-merger warrants and the potential iss","proposal_type":"equity_plan","results":[{"broker_non_votes":"4,520,288","subject":null,"votes_abstain":"25,271","votes_against":"6,662,323","votes_for":"69,026,316","votes_withheld":"0"}]},"claim":"Serina Therapeutics, Inc. shareholders approved Proposal No. 3 – To approve the issuance of the post-merger warrants to holders of AgeX common stock pursuant to the terms of the Merger Agreement, the potential issuance of the incentive warrants and the shares of AgeX common stock upon the exercise of the post-merger warrants and the potential iss at the 2024-03-14 meeting.","evidence_excerpt":"Proposal No. 3 – To approve the issuance of the post-merger warrants to holders of AgeX common stock pursuant to the terms of the Merger Agreement, the potential issuance of the incentive warrants and the shares of AgeX common stock upon the exercise of the post-merger warrants and the potential issuance of shares of AgeX common stock upon the exercise of the incentive warrants, which will represent securities convertible into or exercisable for AgeX common stock of more than 20% of the shares of AgeX common stock outstanding at the time of issuance. Votes  Non-Votes 69,026,316 6,662,323 25,271 4,520,288","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-24-009959","anchor_url":"https://secwatch.observer/filing/0001493152-24-009959#claim-534783b8af64f79b32f3984847b4d1f1ce0d961a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224009959/0001493152-24-009959-index.htm"},{"fact_type":"shareholder_vote","fact_key":"c8c8d9cdf4b3cd45f85a0909c7d255dbb04fd335","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-03-14T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-03-14","outcome":"passed","proposal_text":"Proposal No. 2 – To approve an amendment to the certificate of incorporation of AgeX (the AgeX Charter) to effect a reverse stock split of AgeX common stock at a ratio within the range between 1-for-35 to 1-for-36 with such ratio resulting in approximately 2,500,000 shares of AgeX common stock being","proposal_type":"reverse_split","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"31,505","votes_against":"8,230,746","votes_for":"71,971,946","votes_withheld":"0"}]},"claim":"Serina Therapeutics, Inc. shareholders approved Proposal No. 2 – To approve an amendment to the certificate of incorporation of AgeX (the AgeX Charter) to effect a reverse stock split of AgeX common stock at a ratio within the range between 1-for-35 to 1-for-36 with such ratio resulting in approximately 2,500,000 shares of AgeX common stock being at the 2024-03-14 meeting.","evidence_excerpt":"Proposal No. 2 – To approve an amendment to the certificate of incorporation of AgeX (the AgeX Charter) to effect a reverse stock split of AgeX common stock at a ratio within the range between 1-for-35 to 1-for-36 with such ratio resulting in approximately 2,500,000 shares of AgeX common stock being outstanding immediately prior to the effective time of the Merger, unless otherwise mutually agreed upon by the respective AgeX’s and Serina’s boards of directors prior to the effectiveness of the Merger or, if Proposal Nos. 1, 3, 4 or 6 is not approved by AgeX’s stockholders, with the ratio to be determined solely by the board of directors of AgeX. Votes  Non-Votes 71,971,946 8,230,746 31,505 -","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-24-009959","anchor_url":"https://secwatch.observer/filing/0001493152-24-009959#claim-c8c8d9cdf4b3cd45f85a0909c7d255dbb04fd335","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224009959/0001493152-24-009959-index.htm"},{"fact_type":"shareholder_vote","fact_key":"1dd7a735ae7ac47e3d7cf96e63801ec7f40ad56a","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-03-14T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-03-14","outcome":"passed","proposal_text":"Proposal No. 1 – To approve (i) the issuance of shares of AgeX common stock, which will represent more than 20% of the shares of AgeX common stock outstanding immediately prior to the Merger, to stockholders of Serina, pursuant to the terms of the Merger Agreement, a copy of which is attached as Ann","proposal_type":"merger_approval","results":[{"broker_non_votes":"4,520,288","subject":null,"votes_abstain":"20,290","votes_against":"6,646,481","votes_for":"69,047,139","votes_withheld":"0"}]},"claim":"Serina Therapeutics, Inc. shareholders approved Proposal No. 1 – To approve (i) the issuance of shares of AgeX common stock, which will represent more than 20% of the shares of AgeX common stock outstanding immediately prior to the Merger, to stockholders of Serina, pursuant to the terms of the Merger Agreement, a copy of which is attached as Ann at the 2024-03-14 meeting.","evidence_excerpt":"Proposal No. 1 – To approve (i) the issuance of shares of AgeX common stock, which will represent more than 20% of the shares of AgeX common stock outstanding immediately prior to the Merger, to stockholders of Serina, pursuant to the terms of the Merger Agreement, a copy of which is attached as Annex A to the Proxy Statement/Prospectus/Information Statement, and (ii) the change of control of AgeX resulting from the Merger, pursuant to Sections 712(b) and 713(b) of the NYSE American Company Guide. Votes  Non-Votes 69,047,139 6,646,481 20,290 4,520,288","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-24-009959","anchor_url":"https://secwatch.observer/filing/0001493152-24-009959#claim-1dd7a735ae7ac47e3d7cf96e63801ec7f40ad56a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224009959/0001493152-24-009959-index.htm"},{"fact_type":"debt_financing","fact_key":"3be73c0a90a4d07977ec61344d0b5314d21b1111","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-03-07T23:59:59+00:00","payload":{"counterparty":"Juvenescence Limited","effective_date":"2024-03-05","event":"incurrence","instrument_type":"loan","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"May 9, 2024","principal_text":"$500,000"},"claim":"Serina Therapeutics, Inc. incurred loan of $500,000 with Juvenescence Limited maturing May 9, 2024.","evidence_excerpt":"On March 5, 2024, AgeX Therapeutics, Inc., a Delaware corporation (“AgeX”), drew $500,000 of its credit available under the Amended and Restated Secured Convertible Promissory Note, as amended ( the “Secured Note”), with Juvenescence Limited.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-009224","anchor_url":"https://secwatch.observer/filing/0001493152-24-009224#claim-3be73c0a90a4d07977ec61344d0b5314d21b1111","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224009224/0001493152-24-009224-index.htm"},{"fact_type":"debt_financing","fact_key":"3889a5a446c26897d5ea74fe75363bde98b0a8f9","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-02-14T23:59:59+00:00","payload":{"counterparty":"Juvenescence Limited","effective_date":"2024-02-13","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"May 9, 2024","principal_text":"$500,000"},"claim":"Serina Therapeutics, Inc. incurred convertible notes of $500,000 with Juvenescence Limited maturing May 9, 2024.","evidence_excerpt":"On February 13, 2024, AgeX drew $500,000 of its credit available from Juvenescence under the Secured Note. The Repayment Date on which the outstanding principal balance of the Secured Note will become due and payable shall be May 9, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-006677","anchor_url":"https://secwatch.observer/filing/0001493152-24-006677#claim-3889a5a446c26897d5ea74fe75363bde98b0a8f9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224006677/0001493152-24-006677-index.htm"},{"fact_type":"material_agreement","fact_key":"ba8a3e29963b5c74b8fdbeca580954db5e339071","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-02-14T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Sixth Amendment to Amended and Restated Convertible Promissory Note","agreement_type":"notes_offering","counterparty":"Juvenescence Limited","effective_date":"2024-02-09","item_codes_triggered":["1.01"],"value_text":null},"claim":"Serina Therapeutics, Inc. amended Sixth Amendment to Amended and Restated Convertible Promissory Note with Juvenescence Limited (effective 2024-02-09).","evidence_excerpt":"On February 9, 2024, AgeX and Juvenescence Limited (“Juvenescence”) executed a Sixth Amendment to Amended and Restated Convertible Promissory Note (the “Amendment”) that extends to May 9, 2024 the “Repayment Date” on which the outstanding principal balance and accrued loan origination fees will become due and payable pursuant to the Amended and Restated Secured Convertible Promissory Note, dated February 9, 2023, as previously amended, modified, and restated (the “Secured Note”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-006677","anchor_url":"https://secwatch.observer/filing/0001493152-24-006677#claim-ba8a3e29963b5c74b8fdbeca580954db5e339071","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224006677/0001493152-24-006677-index.htm"},{"fact_type":"debt_financing","fact_key":"f5976e68451ad9ea6c47e5f3001530f819f87d65","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-02-06T23:59:59+00:00","payload":{"counterparty":"Juvenescence Limited","effective_date":"2024-02-01","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"February 14, 2024","principal_text":"$500,000"},"claim":"Serina Therapeutics, Inc. incurred convertible notes of $500,000 with Juvenescence Limited maturing February 14, 2024.","evidence_excerpt":"On February 1, 2024, AgeX Therapeutics, Inc. (“AgeX”) drew $500,000 of its credit available under the Amended and Restated Secured Convertible Promissory Note (as amended, the “Secured Note”) with Juvenescence Limited (“Juvenescence”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-005085","anchor_url":"https://secwatch.observer/filing/0001493152-24-005085#claim-f5976e68451ad9ea6c47e5f3001530f819f87d65","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224005085/0001493152-24-005085-index.htm"},{"fact_type":"debt_financing","fact_key":"b5d90439a7bd3b07538e63c44565a6bff86d9a0e","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-01-19T23:59:59+00:00","payload":{"counterparty":"Juvenescence Limited","effective_date":"2024-01-16","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"February 14, 2024","principal_text":"$500,000"},"claim":"Serina Therapeutics, Inc. incurred convertible notes of $500,000 with Juvenescence Limited maturing February 14, 2024.","evidence_excerpt":"On January 16, 2024, AgeX drew $500,000 of its credit available under the Amended and Restated Secured Convertible Promissory Note, as amended, (“Secured Note”) with Juvenescence Limited (“Juvenescence”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-003057","anchor_url":"https://secwatch.observer/filing/0001493152-24-003057#claim-b5d90439a7bd3b07538e63c44565a6bff86d9a0e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224003057/0001493152-24-003057-index.htm"},{"fact_type":"executive_change","fact_key":"96d4f7a1e7","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-01-11T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-01-08","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Steven Mintz was appointed as Director at Serina Therapeutics, Inc..","evidence_excerpt":"On January 8, 2024, the AgeX Board of Directors increased the size of the Board of Directors (the “Board”) to four directors and appointed Steven Mintz as a director to fill the new vacancy on the Board.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-24-002061","anchor_url":"https://secwatch.observer/filing/0001493152-24-002061#claim-96d4f7a1e7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224002061/0001493152-24-002061-index.htm"},{"fact_type":"debt_financing","fact_key":"4ed45ecbf2997deb9db36e29831bdf4b454ff822","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-01-05T23:59:59+00:00","payload":{"counterparty":"Juvenescence Limited","effective_date":"2024-01-03","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"February 14, 2024","principal_text":"$500,000"},"claim":"Serina Therapeutics, Inc. incurred convertible notes of $500,000 with Juvenescence Limited maturing February 14, 2024.","evidence_excerpt":"On January 3, 2024, AgeX drew $500,000 of its credit available under the Amended and Restated Secured Convertible Promissory Note, as amended, (“Secured Note”) with Juvenescence Limited (“Juvenescence”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-001398","anchor_url":"https://secwatch.observer/filing/0001493152-24-001398#claim-4ed45ecbf2997deb9db36e29831bdf4b454ff822","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224001398/0001493152-24-001398-index.htm"},{"fact_type":"shareholder_vote","fact_key":"5bd8aef1a4a2e9365c0930d19ffe4a8f53dae788","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-12-18T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-12-13","outcome":"passed","proposal_text":"Proposal to permit Juvenescence Limited to acquire additional shares through conversion of Series B Preferred Stock","proposal_type":"other","results":[{"broker_non_votes":"4,847,538","subject":null,"votes_abstain":"38,095","votes_against":"7,461,795","votes_for":"18,908,391","votes_withheld":null}]},"claim":"Serina Therapeutics, Inc. shareholders approved Proposal to permit Juvenescence Limited to acquire additional shares through conversion of Series B Preferred Stock at the 2023-12-13 meeting.","evidence_excerpt":"The Juvenescence was approved by the following vote: Shares Voted For 18,908,391 Against 7,461,795 Abstain 38,095","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-045275","anchor_url":"https://secwatch.observer/filing/0001493152-23-045275#claim-5bd8aef1a4a2e9365c0930d19ffe4a8f53dae788","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223045275/0001493152-23-045275-index.htm"},{"fact_type":"shareholder_vote","fact_key":"0eb87bfa6e19bb9870d23d50b82d78707abe97bd","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-12-18T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-12-13","outcome":"passed","proposal_text":"Ratification of Appointment of Independent Registered Public Accountants","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"496,875","votes_against":"7,298,688","votes_for":"23,460,256","votes_withheld":null}]},"claim":"Serina Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accountants at the 2023-12-13 meeting.","evidence_excerpt":"The appointment of WithumSmith + Brown PC as our independent registered public accountants for the fiscal year ending December 31, 2023 was ratified by the following vote: Shares Voted For 23,460,256 Against 7,298,688 Abstain 496,875","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-045275","anchor_url":"https://secwatch.observer/filing/0001493152-23-045275#claim-0eb87bfa6e19bb9870d23d50b82d78707abe97bd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223045275/0001493152-23-045275-index.htm"},{"fact_type":"shareholder_vote","fact_key":"f4a6eaa2ceaee7f32f14b68277c658aede8e851c","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-12-18T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-12-13","outcome":"passed","proposal_text":"Election of three directors","proposal_type":"director_election","results":[{"broker_non_votes":"4,847,538","subject":"Gregory Bailey","votes_abstain":null,"votes_against":null,"votes_for":"18,629,281","votes_withheld":"7,779,000"},{"broker_non_votes":"4,847,538","subject":"Joanne Hackett","votes_abstain":null,"votes_against":null,"votes_for":"18,946,164","votes_withheld":"7,462,117"},{"broker_non_votes":"4,847,606","subject":"Jean-Christophe Renondin","votes_abstain":null,"votes_against":null,"votes_for":"19,707,041","votes_withheld":"6,701,172"}]},"claim":"Serina Therapeutics, Inc. shareholders approved Election of three directors at the 2023-12-13 meeting.","evidence_excerpt":"Each of the following nominees were elected as directors by the following vote: Nominee Votes For Votes Withheld Gregory Bailey 18,629,281 7,779,000 Joanne Hackett 18,946,164 7,462,117 Jean-Christophe Renondin 19,707,041 6,701,172","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-045275","anchor_url":"https://secwatch.observer/filing/0001493152-23-045275#claim-f4a6eaa2ceaee7f32f14b68277c658aede8e851c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223045275/0001493152-23-045275-index.htm"},{"fact_type":"debt_financing","fact_key":"039d47649d745a0c4840ef4a1d60213e8d5ab9ab","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-12-08T23:59:59+00:00","payload":{"counterparty":"Juvenescence Limited","effective_date":"2023-12-05","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"February 14, 2024","principal_text":"$500,000"},"claim":"Serina Therapeutics, Inc. incurred convertible notes of $500,000 with Juvenescence Limited maturing February 14, 2024.","evidence_excerpt":"On December 5, 2023, AgeX drew $500,000 of its credit available under the Amended and Restated Secured Convertible Promissory Note, as amended, (“Secured Note”) with Juvenescence Limited (“Juvenescence”). The Repayment Date on which the outstanding principal balance of the Secured Note will become due and payable shall be February 14, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-044224","anchor_url":"https://secwatch.observer/filing/0001493152-23-044224#claim-039d47649d745a0c4840ef4a1d60213e8d5ab9ab","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223044224/0001493152-23-044224-index.htm"},{"fact_type":"material_agreement","fact_key":"f4ee36c39e10405a26478a9f8457d653e1d50faf","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-12-01T23:59:59+00:00","payload":{"action":"termination","agreement_name":"Service Agreement with Juvenescence Limited for Dr. Nafees Malik","agreement_type":"other","counterparty":"Juvenescence Limited","effective_date":"2023-12-31","item_codes_triggered":["1.02"],"value_text":"Termination of agreement for Dr. Malik's services; AgeX paid Juvenescence 85% of Dr. Malik's base sa"},"claim":"Serina Therapeutics, Inc. terminated Service Agreement with Juvenescence Limited for Dr. Nafees Malik with Juvenescence Limited valued at Termination of agreement for Dr. Malik's services; AgeX paid Juvenescence 85% of Dr. Malik's base sa (effective 2023-12-31).","evidence_excerpt":"On November 27, 2023, Juvenescence Limited (“Juvenescence”) notified AgeX that Juvenescence is terminating a March 29, 20219 the agreement that incorporated arrangements in effect since October 18, 2018 pursuant to which Juvenescence has provided AgeX with the services of Juvenescence’s employee Nafees Malik who served as Chief Operating Officer of AgeX and our subsidiary Reverse Bioengineering, Inc.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-043393","anchor_url":"https://secwatch.observer/filing/0001493152-23-043393#claim-f4ee36c39e10405a26478a9f8457d653e1d50faf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223043393/0001493152-23-043393-index.htm"},{"fact_type":"executive_change","fact_key":"2f22667abb","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-12-01T23:59:59+00:00","payload":{"action":null,"action_category":"departure","departure_tone":"not_disclosed","effective_date":null,"interim":false,"role":"Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Nafees Malik departed as Chief Operating Officer at Serina Therapeutics, Inc..","evidence_excerpt":"In connection with the termination of the agreement pursuant to which Juvenescence has provided the services of our Chief Operating Officer, Nafees Malik, as set forth in","confidence":0.85,"filing_url":"https://secwatch.observer/filing/0001493152-23-043393","anchor_url":"https://secwatch.observer/filing/0001493152-23-043393#claim-2f22667abb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223043393/0001493152-23-043393-index.htm"},{"fact_type":"debt_financing","fact_key":"bb5d0af26ba1b3584f8a270305c25ac960863293","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-11-17T23:59:59+00:00","payload":{"counterparty":"Juvenescence Limited","effective_date":"2023-11-15","event":"incurrence","instrument_type":"loan","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"February 14, 2024","principal_text":"$500,000"},"claim":"Serina Therapeutics, Inc. incurred loan of $500,000 with Juvenescence Limited maturing February 14, 2024.","evidence_excerpt":"On November 15, 2023, AgeX drew $500,000 of its credit available under the Amended and Restated Secured Convertible Promissory Note, as amended, (“Secured Note”) with Juvenescence Limited (“Juvenescence”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-041874","anchor_url":"https://secwatch.observer/filing/0001493152-23-041874#claim-bb5d0af26ba1b3584f8a270305c25ac960863293","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223041874/0001493152-23-041874-index.htm"},{"fact_type":"earnings_release","fact_key":"8fe21e7d448cdde94acf71b21ec79c55e9fe4661","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-11-14T23:59:59+00:00","payload":{"eps_text":"($0.14) per share (basic and diluted)","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$5.4 million, or ($0.14) per share (basic and diluted)","period_text":"quarter and nine months ended September 30, 2023","report_date":"2023-11-14","result_type":"reported_results","revenue_text":null},"claim":"Serina Therapeutics, Inc. reported quarter and nine months ended September 30, 2023 results: net income $5.4 million, or ($0.14) per share (basic and diluted), EPS ($0.14) per share (basic and diluted).","evidence_excerpt":"AgeX issued a press release announcing its financial results for the quarter and nine months ended September 30, 2023.","confidence":0.85,"filing_url":"https://secwatch.observer/filing/0001493152-23-041156","anchor_url":"https://secwatch.observer/filing/0001493152-23-041156#claim-8fe21e7d448cdde94acf71b21ec79c55e9fe4661","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223041156/0001493152-23-041156-index.htm"},{"fact_type":"debt_financing","fact_key":"8b00d757e77438dc81b62296e2bddbbf8f13879f","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-11-06T23:59:59+00:00","payload":{"counterparty":"Juvenescence Limited","effective_date":"2023-10-31","event":"incurrence","instrument_type":"credit_facility","interest_rate_text":"not disclosed","item_codes_triggered":["2.03"],"maturity_text":"February 14, 2024","principal_text":"$500,000"},"claim":"Serina Therapeutics, Inc. incurred credit facility of $500,000 with Juvenescence Limited at not disclosed maturing February 14, 2024.","evidence_excerpt":"On October 31, 2023, AgeX drew the remaining $500,000 of its credit available under the Amended and Restated Secured Convertible Promissory Note, as amended, (“Secured Note”) with Juvenescence Limited (“Juvenescence”).","confidence":0.92,"filing_url":"https://secwatch.observer/filing/0001493152-23-039514","anchor_url":"https://secwatch.observer/filing/0001493152-23-039514#claim-8b00d757e77438dc81b62296e2bddbbf8f13879f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223039514/0001493152-23-039514-index.htm"},{"fact_type":"debt_financing","fact_key":"3a3d269adb8ae775830db5f2daf39459b2fd3dee","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-10-06T23:59:59+00:00","payload":{"counterparty":"Juvenescence Limited","effective_date":"2023-10-03","event":"incurrence","instrument_type":"loan","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"February 14, 2024","principal_text":"$500,000"},"claim":"Serina Therapeutics, Inc. incurred loan of $500,000 with Juvenescence Limited maturing February 14, 2024.","evidence_excerpt":"On October 3, 2023, AgeX drew $500,000 of its credit available under the Amended and Restated Secured Convertible Promissory Note, as amended, (“Secured Note”) with Juvenescence Limited.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-036495","anchor_url":"https://secwatch.observer/filing/0001493152-23-036495#claim-3a3d269adb8ae775830db5f2daf39459b2fd3dee","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223036495/0001493152-23-036495-index.htm"},{"fact_type":"debt_financing","fact_key":"1eb346a8cc086a5f6802aaec5307e42002e66464","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-09-15T23:59:59+00:00","payload":{"counterparty":"Juvenescence Limited","effective_date":"2023-09-11","event":"incurrence","instrument_type":"loan","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"February 14, 2024","principal_text":"$500,000"},"claim":"Serina Therapeutics, Inc. incurred loan of $500,000 with Juvenescence Limited maturing February 14, 2024.","evidence_excerpt":"On September 11, 2023, AgeX drew $500,000 of its credit available under the Amended and Restated Secured Convertible Promissory Note","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-032759","anchor_url":"https://secwatch.observer/filing/0001493152-23-032759#claim-1eb346a8cc086a5f6802aaec5307e42002e66464","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223032759/0001493152-23-032759-index.htm"},{"fact_type":"executive_change","fact_key":"1070e9060c","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-09-08T23:59:59+00:00","payload":{"action":"does not intend to stand for re-election","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Michael H. May departed as Director at Serina Therapeutics, Inc..","evidence_excerpt":"On September 1, 2023, Dr. Michael H. May informed us that he does not intend to stand for re-election as a director at our next annual meeting of stockholders, which is expected to be held during December of this year.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-032095","anchor_url":"https://secwatch.observer/filing/0001493152-23-032095#claim-1070e9060c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223032095/0001493152-23-032095-index.htm"},{"fact_type":"material_agreement","fact_key":"11820860f25e1520b73c15617237980f93e743c9","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-08-30T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Agreement and Plan of Merger and Reorganization","agreement_type":"merger","counterparty":"AgeX Therapeutics, Inc.","effective_date":"2023-08-29","item_codes_triggered":["1.01"],"value_text":null},"claim":"Serina Therapeutics, Inc. entered into Agreement and Plan of Merger and Reorganization with AgeX Therapeutics, Inc. (effective 2023-08-29).","evidence_excerpt":"On August 29, 2023, AgeX Therapeutics, Inc. (“ AgeX ”) entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”) with Serina Therapeutics Inc., an Alabama corporation (“ Serina ”), and Canaria Transaction Corporation, an Alabama corporation and wholly owned subsidiary of AgeX (“ Merger Sub ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-030618","anchor_url":"https://secwatch.observer/filing/0001493152-23-030618#claim-11820860f25e1520b73c15617237980f93e743c9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223030618/0001493152-23-030618-index.htm"},{"fact_type":"debt_financing","fact_key":"64bdd6d6341879e79b21e4cd0f0dfd4b8020b659","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-08-25T23:59:59+00:00","payload":{"counterparty":"Juvenescence Limited","effective_date":"2023-08-22","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"February 14, 2024","principal_text":"$500,000"},"claim":"Serina Therapeutics, Inc. incurred convertible notes of $500,000 with Juvenescence Limited maturing February 14, 2024.","evidence_excerpt":"On August 22, 2023, AgeX drew $500,000 of its credit available under the Amended and Restated Secured Convertible Promissory Note, as amended, (“Secured Note”) with Juvenescence Limited. The Repayment Date on which the outstanding principal balance of the Secured Note will become due and payable shall be February 14, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-030212","anchor_url":"https://secwatch.observer/filing/0001493152-23-030212#claim-64bdd6d6341879e79b21e4cd0f0dfd4b8020b659","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223030212/0001493152-23-030212-index.htm"},{"fact_type":"earnings_release","fact_key":"7982d0956fa456069071f8333b8cf59f9553ea23","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-08-14T23:59:59+00:00","payload":{"eps_text":"($0.07) per share (basic and diluted)","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$2.7 million net loss attributable to AgeX for the three months ended June 30, 2023","period_text":"second quarter 2023 ended June 30, 2023","report_date":"2023-08-14","result_type":"reported_results","revenue_text":null},"claim":"Serina Therapeutics, Inc. reported second quarter 2023 ended June 30, 2023 results: net income $2.7 million net loss attributable to AgeX for the three months ended June 30, 2023, EPS ($0.07) per share (basic and diluted).","evidence_excerpt":"the net loss attributable to AgeX for the three months ended June 30, 2023 was $2.7 million, or ($0.07) per share (basic and diluted) compared to $2.6 million, or ($0.07) per share (basic and diluted), for 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-028506","anchor_url":"https://secwatch.observer/filing/0001493152-23-028506#claim-7982d0956fa456069071f8333b8cf59f9553ea23","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223028506/0001493152-23-028506-index.htm"},{"fact_type":"debt_financing","fact_key":"311af0a2415cd86c6ddc672a15f87c62476fe2e9","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-08-04T23:59:59+00:00","payload":{"counterparty":"Juvenescence Limited","effective_date":"2023-08-01","event":"incurrence","instrument_type":"credit_facility","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"February 14, 2024","principal_text":"$500,000"},"claim":"Serina Therapeutics, Inc. incurred credit facility of $500,000 with Juvenescence Limited maturing February 14, 2024.","evidence_excerpt":"On August 1, 2023, AgeX drew $500,000 of its credit available under the Secured Note as amended by the Fourth Amendment.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-026840","anchor_url":"https://secwatch.observer/filing/0001493152-23-026840#claim-311af0a2415cd86c6ddc672a15f87c62476fe2e9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223026840/0001493152-23-026840-index.htm"},{"fact_type":"material_agreement","fact_key":"82c42503eb63ff8b2c38e0ef183c57cb57905b69","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-08-04T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Fourth Amendment to the Amended and Restated Secured Convertible Promissory Note","agreement_type":"credit_facility","counterparty":"Juvenescence Limited","effective_date":"2023-07-31","item_codes_triggered":["1.01","1.02"],"value_text":"extended Reverse Financing Condition deadline to October 31, 2023; Juvenescence may convert without"},"claim":"Serina Therapeutics, Inc. entered into Fourth Amendment to the Amended and Restated Secured Convertible Promissory Note with Juvenescence Limited valued at extended Reverse Financing Condition deadline to October 31, 2023; Juvenescence may convert without (effective 2023-07-31).","evidence_excerpt":"On July 31, 2023, AgeX and Juvenescence Limited (“Juvenescence”) entered into a Fourth Amendment (the “Fourth Amendment”) to the Amended and Restated Secured Convertible Promissory Note (the “Secured Note”) to provide that (i) the definition of Reverse Financing Condition is amended to extend to October 31, 2023 the referenced deadline for fulfillment of the condition to permit borrowing or other incurrence of indebtedness by AgeX’s subsidiary Reverse Bioengineering, Inc., and (ii) Juvenescence may convert the outstanding amount of the Secured Note loans or any portion of such loans into AgeX common stock without restriction by the “19.9% Cap” if Juvenescence elects to convert those amounts at a conversion price or prices equal to the “Drawdown Market Prices” applicable to such loan amounts in lieu of a lower conversion price set with reference to the current market price of AgeX common stock at the time of conversion.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-026840","anchor_url":"https://secwatch.observer/filing/0001493152-23-026840#claim-82c42503eb63ff8b2c38e0ef183c57cb57905b69","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223026840/0001493152-23-026840-index.htm"},{"fact_type":"material_agreement","fact_key":"5f5e071bb7c8320d74665696b4a6f2d41fb8b414","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-07-21T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Registration Rights Agreement","agreement_type":"other","counterparty":"Juvenescence Limited","effective_date":"2023-07-21","item_codes_triggered":["1.01"],"value_text":null},"claim":"Serina Therapeutics, Inc. entered into Registration Rights Agreement with Juvenescence Limited (effective 2023-07-21).","evidence_excerpt":"AgeX and Juvenescence have entered into a Registration Rights Agreement pursuant to which AgeX has agreed to use commercially reasonable efforts to register the for sale under the Securities Act of 1933, as amended (the “Securities Act”) the shares of common stock issuable upon conversion of Preferred Stock.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-025290","anchor_url":"https://secwatch.observer/filing/0001493152-23-025290#claim-5f5e071bb7c8320d74665696b4a6f2d41fb8b414","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223025290/0001493152-23-025290-index.htm"},{"fact_type":"material_agreement","fact_key":"bda5f4646a0467868822a2ca1491c92b99103ffd","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-07-21T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Exchange Agreement","agreement_type":"equity_purchase","counterparty":"Juvenescence Limited","effective_date":"2023-07-21","item_codes_triggered":["1.01"],"value_text":"$36 Million"},"claim":"Serina Therapeutics, Inc. entered into Exchange Agreement with Juvenescence Limited valued at $36 Million (effective 2023-07-21).","evidence_excerpt":"On July 21, 2023, AgeX and Juvenescence Limited (“Juvenescence”) entered into an Exchange Agreement pursuant to which AgeX agreed to issue to Juvenescence 211,600 shares of a newly authorized Series A Preferred Stock and 148,400 shares of a newly authorized Series B Preferred Stock in exchange for the cancellation of a total of $36 Million of indebtedness","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-025290","anchor_url":"https://secwatch.observer/filing/0001493152-23-025290#claim-bda5f4646a0467868822a2ca1491c92b99103ffd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223025290/0001493152-23-025290-index.htm"},{"fact_type":"debt_financing","fact_key":"e472659341a285e3534537317755fae08d796e5d","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-07-07T23:59:59+00:00","payload":{"counterparty":null,"effective_date":"2023-07-05","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"February 14, 2024","principal_text":"$500,000"},"claim":"Serina Therapeutics, Inc. incurred convertible notes of $500,000 maturing February 14, 2024.","evidence_excerpt":"On July 5, 2023, AgeX drew $500,000 of its credit available under the Allonge and Restated Convertible Promissory Note (“Secured Note”) as amended on June 2, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-023975","anchor_url":"https://secwatch.observer/filing/0001493152-23-023975#claim-e472659341a285e3534537317755fae08d796e5d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223023975/0001493152-23-023975-index.htm"},{"fact_type":"debt_financing","fact_key":"f05c0aa1e6d52edc8a7d1073ff996f48defe8af4","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-06-08T23:59:59+00:00","payload":{"counterparty":"Juvenescence Ltd","effective_date":"2023-06-07","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"February 14, 2024","principal_text":"$500,000"},"claim":"Serina Therapeutics, Inc. incurred convertible notes of $500,000 with Juvenescence Ltd maturing February 14, 2024.","evidence_excerpt":"On June 7, 2023, AgeX drew $500,000 of its credit available under the Secured Note as most recently amended by the Third Amendment.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-020563","anchor_url":"https://secwatch.observer/filing/0001493152-23-020563#claim-f05c0aa1e6d52edc8a7d1073ff996f48defe8af4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223020563/0001493152-23-020563-index.htm"},{"fact_type":"material_agreement","fact_key":"bda0e2034e714aa1a4834d5ef8c6563ae6d34aec","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-06-08T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Third Amendment to Amended and Restated Convertible Promissory Note","agreement_type":"notes_offering","counterparty":"Juvenescence Limited","effective_date":"2023-06-02","item_codes_triggered":["1.01"],"value_text":null},"claim":"Serina Therapeutics, Inc. amended Third Amendment to Amended and Restated Convertible Promissory Note with Juvenescence Limited (effective 2023-06-02).","evidence_excerpt":"On June 2, 2023 AgeX and Juvenescence Limited (“Juvenescence”) entered into an amendment to the Amended and Restated Secured Convertible Promissory Note (the “Secured Note”), as previously amended by an Allonge and Second Amendment to Amended and Restated Convertible Promissory Note (the “Second Amendment”), to provide that (i) AgeX may draw on the available portion of the line of credit under the Secured Note until the earlier of the date a Qualified Offering as defined in the Secured Note is consummated by AgeX or October 31, 2023 (subject to Juvenescence’s discretion to approve each loan draw as provided in the Secured Note), (ii) AgeX will not be obligated to issue additional common stock purchase warrants to Juvenescence in connection with the receipt of loan funds made available pursuant to the Second Amendment, and (iii) the definition of Reverse Financing Condition is amended to extend to June 20, 2023 the referenced deadline for fulfillment of the condition to permit borrowing","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-020563","anchor_url":"https://secwatch.observer/filing/0001493152-23-020563#claim-bda0e2034e714aa1a4834d5ef8c6563ae6d34aec","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223020563/0001493152-23-020563-index.htm"},{"fact_type":"debt_financing","fact_key":"8944aff2bad1d394db6d53638eddf25eda25e55c","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-05-23T23:59:59+00:00","payload":{"counterparty":"Juvenescence Limited","effective_date":"2023-05-19","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"February 14, 2024","principal_text":"$500,000"},"claim":"Serina Therapeutics, Inc. incurred convertible notes of $500,000 with Juvenescence Limited maturing February 14, 2024.","evidence_excerpt":"On May 19, 2023, AgeX drew $500,000 of its credit available under the Allonge and Second Amendment to Amended and Restated Convertible Promissory Note (“Secured Note”) dated May 9, 2023 with Juvenescence Limited (“Juvenescence”). The Repayment Date on which the outstanding principal balance of the Secured Note will become due and payable shall be February 14, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-018725","anchor_url":"https://secwatch.observer/filing/0001493152-23-018725#claim-8944aff2bad1d394db6d53638eddf25eda25e55c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223018725/0001493152-23-018725-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"18f9850b94fb5baf27dcfc3cf8d7d9f51c53809e","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-05-23T23:59:59+00:00","payload":{"company_response":"intends to timely request a hearing","compliance_status":"hearing_requested","cure_deadline":"2023-05-17","deficiency_type":"stockholders_equity","delisting_effective_date":null,"exchange":"nyse_american","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2023-05-17","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":"Sections 1003(a)(i), (ii) and (iii) of the Exchange's Company Guide","reported_value":null,"rule_numbers":["1003(a)(i)","1003(a)(ii)","1003(a)(iii)"],"rules_cited_in_text":true},"claim":"Serina Therapeutics, Inc. received a nyse_american delisting notice notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii), 1003(a)(iii)).","evidence_excerpt":"May 17, 2023, AgeX received a notice from the staff of the NYSE American (the “Exchange”) indicating that they intend to\ncommence proceedings to delist AgeX common stock from the Exchange based upon AgeX’s non-compliance with the stockholders’\nequity requirements set forth in Sections 1003(a)(i), (ii) and (iii) of the Exchange’s Company Guide by the end of a compliance\nplan period that expired on May 17, 2023. Specifically, AgeX does not meet the continued listing standards because it has stockholders\nequity of less than (A) $2,000,000 and has incurred losses from continuing operations and/or","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-018725","anchor_url":"https://secwatch.observer/filing/0001493152-23-018725#claim-18f9850b94fb5baf27dcfc3cf8d7d9f51c53809e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223018725/0001493152-23-018725-index.htm"},{"fact_type":"earnings_release","fact_key":"0b9a6c1f47f8830ed749a1625d088ac2de7de1f2","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-05-12T23:59:59+00:00","payload":{"eps_text":"($0.09) per share (basic and diluted)","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$3.3 million","period_text":"quarter ended March 31, 2023","report_date":"2023-05-12","result_type":"reported_results","revenue_text":"$10,000"},"claim":"Serina Therapeutics, Inc. reported quarter ended March 31, 2023 results: revenue $10,000, net income $3.3 million, EPS ($0.09) per share (basic and diluted).","evidence_excerpt":"and fund each of AgeX’s future draws of that additional amount of credit. First Quarter 2023 Operating Results Revenues: Total Revenues for the first quarter\nof 2023 were $10,000 as compared with $5,000 in the same period in 2022. Revenues are entirely comprised of sales of research products\nincluding stem cell products. Operating expenses: Operating","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-016659","anchor_url":"https://secwatch.observer/filing/0001493152-23-016659#claim-0b9a6c1f47f8830ed749a1625d088ac2de7de1f2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223016659/0001493152-23-016659-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"3ef3faa96177bbc7127a34bb8ca2fa25e9160e09","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-04-26T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2023-05-17","deficiency_type":"stockholders_equity","delisting_effective_date":null,"exchange":"nyse_american","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"stockholders equity less than $2,000,000 (or $4,000,000, or $6,000,000) with losses","notice_date":"2023-04-20","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"Sections 1003(a)(i), (ii), and (iii) of the Exchange Company Guide","reported_value":null,"rule_numbers":["1003(a)(i)","1003(a)(ii)","1003(a)(iii)"],"rules_cited_in_text":true},"claim":"Serina Therapeutics, Inc. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii), 1003(a)(iii)).","evidence_excerpt":"April 20, 2023, AgeX received a letter (the “Deficiency Letter”) from the staff of the NYSE American (the\n“Exchange”) indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth\nin Sections 1003(a)(i), (ii), and (iii) of the Exchange Company Guide in that AgeX has stockholders equity of less than (A)\n$2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years, (B)\n$4,000,000 and has incurred losses from continuing operations and/or net losses during three out of four of its most recent fiscal","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-013662","anchor_url":"https://secwatch.observer/filing/0001493152-23-013662#claim-3ef3faa96177bbc7127a34bb8ca2fa25e9160e09","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223013662/0001493152-23-013662-index.htm"},{"fact_type":"debt_financing","fact_key":"fce726b642e8902b82c4d24effcd454aa1bbba15","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-04-06T23:59:59+00:00","payload":{"counterparty":"Juvenescence Limited","effective_date":"2023-04-04","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"February 14, 2024","principal_text":"$1 million"},"claim":"Serina Therapeutics, Inc. incurred convertible notes of $1 million with Juvenescence Limited maturing February 14, 2024.","evidence_excerpt":"On April 4, 2023, AgeX drew the remaining $1 million of its credit available under the Amended and Restated Secured Convertible Promissory Note (“Secured Note”) dated February 9, 2023 with Juvenescence Limited (“Juvenescence”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-011242","anchor_url":"https://secwatch.observer/filing/0001493152-23-011242#claim-fce726b642e8902b82c4d24effcd454aa1bbba15","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223011242/0001493152-23-011242-index.htm"},{"fact_type":"earnings_release","fact_key":"7417be1efa64126ba18e3d80d5a2d10e488d2bd5","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-03-31T23:59:59+00:00","payload":{"eps_text":"($0.28) per share (basic and diluted)","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss attributable to AgeX for the year ended December 31, 2022 was $10.5 million","period_text":"fourth quarter and fiscal year ended December 31, 2022","report_date":"2023-03-31","result_type":"reported_results","revenue_text":"Total revenues for the fourth quarter of 2022 were $8,000 as compared with $27,000 for the fourth quarter of 2021. Total"},"claim":"Serina Therapeutics, Inc. reported fourth quarter and fiscal year ended December 31, 2022 results: revenue Total revenues for the fourth quarter of 2022 were $8,000 as compared with $27,000 for the fourth quarter of 2021. Total, net income Net loss attributable to AgeX for the year ended December 31, 2022 was $10.5 million, EPS ($0.28) per share (basic and diluted).","evidence_excerpt":"AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-010315","anchor_url":"https://secwatch.observer/filing/0001493152-23-010315#claim-7417be1efa64126ba18e3d80d5a2d10e488d2bd5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223010315/0001493152-23-010315-index.htm"},{"fact_type":"debt_financing","fact_key":"951b4d17a461c5d84e42c58cb7e28b5d32a9de2b","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-03-15T23:59:59+00:00","payload":{"counterparty":"Juvenescence Limited","effective_date":"2023-03-14","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"origination fee in an amount equal to 7% of the loan funds disbursed to AgeX","item_codes_triggered":["2.03"],"maturity_text":"March 13, 2026","principal_text":"$10,000,000"},"claim":"Serina Therapeutics, Inc. incurred convertible notes of $10,000,000 with Juvenescence Limited at origination fee in an amount equal to 7% of the loan funds disbursed to AgeX maturing March 13, 2026.","evidence_excerpt":"(“ AgeX ”) and Juvenescence Limited (“ Juvenescence ”)\nentered into a Secured Convertible Promissory Note (the “ Juvenescence Note ”) pursuant to which Juvenescence","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-007763","anchor_url":"https://secwatch.observer/filing/0001493152-23-007763#claim-951b4d17a461c5d84e42c58cb7e28b5d32a9de2b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223007763/0001493152-23-007763-index.htm"},{"fact_type":"material_agreement","fact_key":"c76079b083206b7d8e34725429fa8bdf18c5ac16","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-03-15T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Convertible Note Purchase Agreement","agreement_type":"credit_facility","counterparty":"AgeX Therapeutics, Inc.","effective_date":"2023-03-15","item_codes_triggered":["1.01"],"value_text":"$10,000,000"},"claim":"Serina Therapeutics, Inc. entered into Convertible Note Purchase Agreement with AgeX Therapeutics, Inc. valued at $10,000,000 (effective 2023-03-15).","evidence_excerpt":"Serina Therapeutics Inc., an Alabama corporation (“ Serina ”) to AgeX on March 15, 2023, pursuant to the terms of a Convertible Note Purchase Agreement, dated March 15, 2023 (the “ Serina Note Purchase Agreement ”), between AgeX and Serina.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-007763","anchor_url":"https://secwatch.observer/filing/0001493152-23-007763#claim-c76079b083206b7d8e34725429fa8bdf18c5ac16","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223007763/0001493152-23-007763-index.htm"},{"fact_type":"executive_change","fact_key":"5d024f87c6","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-03-15T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-03-09","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Dr. Michael D. West resigned as Director at Serina Therapeutics, Inc..","evidence_excerpt":"On March 9, 2023, Dr. Michael D. West resigned from AgeX’s Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-007763","anchor_url":"https://secwatch.observer/filing/0001493152-23-007763#claim-5d024f87c6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223007763/0001493152-23-007763-index.htm"},{"fact_type":"debt_financing","fact_key":"75f67463f7000c1a24b1bec5e208e5f625b2c4dc","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-02-17T23:59:59+00:00","payload":{"counterparty":"Juvenescence Limited","effective_date":"2023-02-15","event":"incurrence","instrument_type":"senior_notes","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"February 14, 2024","principal_text":"$1 million"},"claim":"Serina Therapeutics, Inc. incurred senior notes of $1 million with Juvenescence Limited maturing February 14, 2024.","evidence_excerpt":"On February 15, 2023, AgeX drew $1 million of its available credit under the Amended and Restated Secured Convertible Promissory Note (“Amended Note”) dated February 9, 2023 with Juvenescence Limited (“Juvenescence”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-005435","anchor_url":"https://secwatch.observer/filing/0001493152-23-005435#claim-75f67463f7000c1a24b1bec5e208e5f625b2c4dc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223005435/0001493152-23-005435-index.htm"},{"fact_type":"material_agreement","fact_key":"b431f8fe138bfe86ea5bdfb1ff2d121aee29fdc5","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-02-10T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Reaffirmation and Amendment Agreement","agreement_type":"other","counterparty":"Juvenescence Limited","effective_date":"2023-02-09","item_codes_triggered":["1.01"],"value_text":null},"claim":"Serina Therapeutics, Inc. entered into Reaffirmation and Amendment Agreement with Juvenescence Limited (effective 2023-02-09).","evidence_excerpt":"In connection with the Amended Note, AgeX and Juvenescence entered into a Reaffirmation and Amendment Agreement (the \"Reaffirmation Agreement\") pursuant to which AgeX reaffirmed its obligations under certain agreements between AgeX and Juvenescence that originally pertained to the Original Note, including but not limited to (i) the Security Agreement, (ii) a Registration Rights Agreement, as amended, and (iii) a Warrant Agreement.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-004279","anchor_url":"https://secwatch.observer/filing/0001493152-23-004279#claim-b431f8fe138bfe86ea5bdfb1ff2d121aee29fdc5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223004279/0001493152-23-004279-index.htm"},{"fact_type":"material_agreement","fact_key":"e8b222a3b7a466b9ad63f06f91513cd860ab8c20","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-02-10T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Amended and Restated Secured Convertible Promissory Note","agreement_type":"notes_offering","counterparty":"Juvenescence Limited","effective_date":"2023-02-09","item_codes_triggered":["1.01"],"value_text":"additional $2,000,000"},"claim":"Serina Therapeutics, Inc. entered into Amended and Restated Secured Convertible Promissory Note with Juvenescence Limited valued at additional $2,000,000 (effective 2023-02-09).","evidence_excerpt":"On February 9, 2023, AgeX and Juvenescence Limited (\"Juvenescence\") entered into an Amended and Restated Secured Convertible Promissory Note (the \"Amended Note\") which amends and restates a February 14, 2022 Secured Convertible Promissory Note (the \"Original Note\") and provides that AgeX may borrow up to an additional $2,000,000 from Juvenescence until May 9, 2023 subject to Juvenescence’s discretion to approve each loan draw.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-004279","anchor_url":"https://secwatch.observer/filing/0001493152-23-004279#claim-e8b222a3b7a466b9ad63f06f91513cd860ab8c20","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223004279/0001493152-23-004279-index.htm"},{"fact_type":"debt_financing","fact_key":"ff1643f14cf639dd3cf08ac6d52b31c813d17942","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-01-27T23:59:59+00:00","payload":{"counterparty":"Juvenescence Limited","effective_date":"2023-01-25","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"4% of the amount each draw of loan funds","item_codes_triggered":["2.03"],"maturity_text":"February 14, 2024","principal_text":"$500,000"},"claim":"Serina Therapeutics, Inc. incurred convertible notes of $500,000 with Juvenescence Limited at 4% of the amount each draw of loan funds maturing February 14, 2024.","evidence_excerpt":"On January 25, 2023, AgeX borrowed the remaining $500,000 under the Secured Convertible Promissory Note (the “Secured Note”) dated as of February 14, 2022 with Juvenescence Limited (“Juvenescence”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-002757","anchor_url":"https://secwatch.observer/filing/0001493152-23-002757#claim-ff1643f14cf639dd3cf08ac6d52b31c813d17942","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223002757/0001493152-23-002757-index.htm"},{"fact_type":"debt_financing","fact_key":"9e834d2415ba5a4bd3b7a927882f8bf752775163","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2022-12-16T23:59:59+00:00","payload":{"counterparty":"Juvenescence Limited","effective_date":"2022-12-14","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"4% of the amount each draw of loan funds, which will accrue as each draw is fund","item_codes_triggered":["2.03"],"maturity_text":"February 14, 2024","principal_text":"$1,000,000"},"claim":"Serina Therapeutics, Inc. incurred convertible notes of $1,000,000 with Juvenescence Limited at 4% of the amount each draw of loan funds, which will accrue as each draw is fund maturing February 14, 2024.","evidence_excerpt":"On December 14, 2022, AgeX borrowed an additional $1,000,000 under the Secured Convertible Promissory Note (the “Secured Note”) dated as of February 14, 2022 with Juvenescence Limited (“Juvenescence”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-22-035736","anchor_url":"https://secwatch.observer/filing/0001493152-22-035736#claim-9e834d2415ba5a4bd3b7a927882f8bf752775163","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315222035736/0001493152-22-035736-index.htm"},{"fact_type":"shareholder_vote","fact_key":"e18dcee5065bd23cbf447eba0b6b882d1856125d","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2022-12-12T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-12-07","outcome":"passed","proposal_text":"Juvenescence Proposal - to permit Juvenescence Limited to acquire additional shares of AgeX common stock through exercise of warrants or conversion of loans","proposal_type":"other","results":[{"broker_non_votes":"5,244,408","subject":null,"votes_abstain":"56,676","votes_against":"1,204,612","votes_for":"20,393,670","votes_withheld":null}]},"claim":"Serina Therapeutics, Inc. shareholders approved Juvenescence Proposal - to permit Juvenescence Limited to acquire additional shares of AgeX common stock through exercise of warrants or conversion of loans at the 2022-12-07 meeting.","evidence_excerpt":"Juvenescence Proposal The Juvenescence was approved by the following vote: Shares Voted For 20,393,670 Against 1,204,612 Abstain 56,676 In addition, there were 5,244,408 broker non-votes on this matter.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-22-035162","anchor_url":"https://secwatch.observer/filing/0001493152-22-035162#claim-e18dcee5065bd23cbf447eba0b6b882d1856125d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315222035162/0001493152-22-035162-index.htm"},{"fact_type":"shareholder_vote","fact_key":"3120e897fb4fa48a08f00a1e1ffde61174fc79bc","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2022-12-12T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-12-07","outcome":"passed","proposal_text":"Incentive Plan Amendment Proposal - amendment of 2017 Equity Incentive Plan to make additional 4,000,000 shares available","proposal_type":"equity_plan","results":[{"broker_non_votes":"5,244,408","subject":null,"votes_abstain":"53,488","votes_against":"1,474,349","votes_for":"20,127,120","votes_withheld":null}]},"claim":"Serina Therapeutics, Inc. shareholders approved Incentive Plan Amendment Proposal - amendment of 2017 Equity Incentive Plan to make additional 4,000,000 shares available at the 2022-12-07 meeting.","evidence_excerpt":"Incentive Plan Amendment Proposal The Incentive Plan Amendment Proposal was approved by the following vote: Shares Voted For 20,127,120 Against 1,474,349 Abstain 53,488 In addition, there were 5,244,408 broker non-votes on this matter.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-22-035162","anchor_url":"https://secwatch.observer/filing/0001493152-22-035162#claim-3120e897fb4fa48a08f00a1e1ffde61174fc79bc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315222035162/0001493152-22-035162-index.htm"},{"fact_type":"shareholder_vote","fact_key":"07a5556e8437318d809e8448981feb5df5dbcb8a","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2022-12-12T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-12-07","outcome":"passed","proposal_text":"Common Stock Amendment Proposal - amendment to Certificate of Incorporation to increase authorized shares from 100,000,000 to 200,000,000","proposal_type":"charter_amendment","results":[{"broker_non_votes":"4,736,638","subject":null,"votes_abstain":"22,781","votes_against":"1,341,037","votes_for":"20,798,910","votes_withheld":null}]},"claim":"Serina Therapeutics, Inc. shareholders approved Common Stock Amendment Proposal - amendment to Certificate of Incorporation to increase authorized shares from 100,000,000 to 200,000,000 at the 2022-12-07 meeting.","evidence_excerpt":"Common Stock Amendment Proposal The Common Stock Amendment Proposal was approved by the following vote: Shares Voted For 20,798,910 Against 1,341,037 Abstain 22,781 In addition, there were 4,736,638 broker non-votes on this matter.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-22-035162","anchor_url":"https://secwatch.observer/filing/0001493152-22-035162#claim-07a5556e8437318d809e8448981feb5df5dbcb8a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315222035162/0001493152-22-035162-index.htm"},{"fact_type":"shareholder_vote","fact_key":"4696cb2e1cb2c6c096cea10de84237664580c817","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2022-12-12T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-12-07","outcome":"passed","proposal_text":"Ratification of Appointment of Independent Registered Public Accountants","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"90,923","votes_against":"31,458","votes_for":"26,776,985","votes_withheld":null}]},"claim":"Serina Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accountants at the 2022-12-07 meeting.","evidence_excerpt":"Ratification of Appointment of Independent Registered Public Accountants The appointment of WithumSmith + Brown PC as our independent registered public accountants for the fiscal year ending December 31, 2022 was ratified by the following vote: Shares Voted For 26,776,985 Against 31,458 Abstain 90,923 There were no broker non-votes on this matter.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-22-035162","anchor_url":"https://secwatch.observer/filing/0001493152-22-035162#claim-4696cb2e1cb2c6c096cea10de84237664580c817","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315222035162/0001493152-22-035162-index.htm"},{"fact_type":"shareholder_vote","fact_key":"c3da56e6408f19e3dadd1ead39da5eebad3a219c","cik":1708599,"ticker":"SER","company_name":"Serina Therapeutics, Inc.","filed_at":"2022-12-12T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-12-07","outcome":"passed","proposal_text":"Election of Directors","proposal_type":"director_election","results":[{"broker_non_votes":"5,244,408","subject":"Gregory Bailey","votes_abstain":null,"votes_against":null,"votes_for":"20,443,999","votes_withheld":"1,210,959"},{"broker_non_votes":"5,244,408","subject":"Joanne Hackett","votes_abstain":null,"votes_against":null,"votes_for":"20,457,478","votes_withheld":"1,197,480"},{"broker_non_votes":"5,244,408","subject":"Michael May","votes_abstain":null,"votes_against":null,"votes_for":"20,469,901","votes_withheld":"1,185,057"},{"broker_non_votes":"5,244,408","subject":"Michael D. West","votes_abstain":null,"votes_against":null,"votes_for":"20,685,723","votes_withheld":"969,235"}]},"claim":"Serina Therapeutics, Inc. shareholders approved Election of Directors at the 2022-12-07 meeting.","evidence_excerpt":"Election of Directors Each of the following nominees were elected as directors by the following vote: Nominee Votes For Votes Withheld Gregory Bailey 20,443,999 1,210,959 Joanne Hackett 20,457,478 1,197,480 Michael May 20,469,901 1,185,057 Michael D. West 20,685,723 969,235 In addition, there were 5,244,408 broker non-votes with respect to the election of directors.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-22-035162","anchor_url":"https://secwatch.observer/filing/0001493152-22-035162#claim-c3da56e6408f19e3dadd1ead39da5eebad3a219c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315222035162/0001493152-22-035162-index.htm"}]}